PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24396144-11	2014	Inhibiting P-gp-mediated efflux by elacridar in in vitro experiments significantly decreased fexofenadine efflux from hepatocytes, resulting in an increase in apparent fexofenadine uptake.	fexofenadine	93-105	phosphoglycolate phosphatase	Homo sapiens	11-15
25020133-8	2014	Interestingly, the expression of iNOS and eNOS mRNA was increased in aortas of mice on high doses of cetirizine or fexofenadine.	fexofenadine	115-127	nitric oxide synthase 3, endothelial cell	Mus musculus	42-46
24549825-1	2014	PURPOSE: OATP2B1-mediated grapefruit juice (GFJ)-drug interactions are substrate-dependent; for example, GFJ ingestion significantly reduces bioavailability of fexofenadine, but not pravastatin.	fexofenadine	160-172	solute carrier organic anion transporter family member 2B1 L homeolog	Xenopus laevis	9-16
24549825-5	2014	RESULTS: OATP2B1-mediated uptake of pravastatin and fexofenadine exhibited biphasic saturation kinetics, indicating the presence of MBS on OATP2B1.	fexofenadine	52-64	solute carrier organic anion transporter family member 2B1 L homeolog	Xenopus laevis	9-16
24549825-5	2014	RESULTS: OATP2B1-mediated uptake of pravastatin and fexofenadine exhibited biphasic saturation kinetics, indicating the presence of MBS on OATP2B1.	fexofenadine	52-64	solute carrier organic anion transporter family member 2B1 L homeolog	Xenopus laevis	139-146
24549825-9	2014	These findings indicate that only fexofenadine is expected to interact with GFJ on OATP2B1 at therapeutic concentrations, in accordance with the clinical observations.	fexofenadine	34-46	solute carrier organic anion transporter family member 2B1 L homeolog	Xenopus laevis	83-90
24396144-11	2014	Inhibiting P-gp-mediated efflux by elacridar in in vitro experiments significantly decreased fexofenadine efflux from hepatocytes, resulting in an increase in apparent fexofenadine uptake.	fexofenadine	168-180	phosphoglycolate phosphatase	Homo sapiens	11-15
24138758-8	2013	Fexofenadine (a peripherally acting histamine H1 receptor antagonist) reduced MM activity in normal mice.	fexofenadine	0-12	histamine receptor H1	Mus musculus	36-57
24782370-1	2014	OBJECTIVE: To establish a precolumn chiral derivatization method for determination of fexofenadine enantiomers, a chiral substrate of OATP1B1, in cellular model.	fexofenadine	86-98	solute carrier organic anion transporter family member 1B1	Homo sapiens	134-141
24423593-2	2014	P-gp (fexofenadine) and CYP-specific substrates (caffeine for CYP1A2, bupropion for CYP2B6, flurbiprofen for CYP2C9, omeprazole for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4) and their metabolites were extracted from DBS (10 microl) using methanol.	fexofenadine	6-18	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
24040855-0	2013	The role of multidrug resistance-1 (MDR1) variants in response to fexofenadine among Jordanians.	fexofenadine	66-78	ATP binding cassette subfamily B member 1	Homo sapiens	12-34
24040855-0	2013	The role of multidrug resistance-1 (MDR1) variants in response to fexofenadine among Jordanians.	fexofenadine	66-78	ATP binding cassette subfamily B member 1	Homo sapiens	36-40
24040855-2	2013	The P-gp has wide substrate specificity for multiple medications, including the antiallergic drug fexofenadine.	fexofenadine	98-110	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
24040855-3	2013	In this study, we investigated the possible association between three common MDR1 gene polymorphisms (G2677T, C3435T, and C1236T), and the anti-allergic effect of fexofenadine among Jordanians.	fexofenadine	163-175	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
24040855-11	2013	CONCLUSIONS: The MDR1 gene polymorphism C1236T was associated with the anti-allergic effect of fexofenadine among male Jordanians.	fexofenadine	95-107	ATP binding cassette subfamily B member 1	Homo sapiens	17-21
23369146-8	2013	The fentanyl-induced enhancement of the number of citric acid-induced coughs was abolished in mice that had been pretreated with moguisteine, a rapidly adapting receptor (RAR) antagonist or fexofenadine, a histamine H1 receptor antagonist.	fexofenadine	190-202	histamine receptor H1	Mus musculus	206-227
23422332-7	2013	Fexofenadine was used as a P-gp phenotyping probe.	fexofenadine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	27-31
23422332-15	2013	In the placebo phase, T1/2 of fexofenadine in ABCB1 3435T mutation allele carriers was longer compared to ABCB1 3435CC carriers (4.43+-1.44h vs. 2.54+-0.21h, p<0.05).	fexofenadine	30-42	ATP binding cassette subfamily B member 1	Homo sapiens	46-51
21646440-2	2012	The purpose of this study was to determine the influence of Panax ginseng on CYP3A and P-gp function using the probe substrates midazolam and fexofenadine, respectively.	fexofenadine	142-154	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-82
23115085-5	2013	Rifampicin inhibited the uptake of fexofenadine enantiomers by human hepatocytes via organic anion transporter (OAT) OATP1B3 and its basal-to-apical transport in Caco-2 cells, but not OAT3-mediated or multidrug and toxic compound extrusion 1 (MATE1)-mediated transport.	fexofenadine	35-47	solute carrier organic anion transporter family member 1B3	Homo sapiens	117-124
23115085-5	2013	Rifampicin inhibited the uptake of fexofenadine enantiomers by human hepatocytes via organic anion transporter (OAT) OATP1B3 and its basal-to-apical transport in Caco-2 cells, but not OAT3-mediated or multidrug and toxic compound extrusion 1 (MATE1)-mediated transport.	fexofenadine	35-47	solute carrier family 22 member 8	Homo sapiens	184-188
23115085-5	2013	Rifampicin inhibited the uptake of fexofenadine enantiomers by human hepatocytes via organic anion transporter (OAT) OATP1B3 and its basal-to-apical transport in Caco-2 cells, but not OAT3-mediated or multidrug and toxic compound extrusion 1 (MATE1)-mediated transport.	fexofenadine	35-47	solute carrier family 47 member 1	Homo sapiens	243-248
23115085-8	2013	S-fexofenadine is a more potent human histamine H1 receptor antagonist than R-fexofenadine.	fexofenadine	0-14	histamine receptor H1	Homo sapiens	38-59
23115085-9	2013	In conclusion, rifampicin has multiple interaction sites with fexofenadine, all of which contribute to increasing the area under the curve of fexofenadine when they are given simultaneously, to surpass the effect of the induction of P-glycoprotein elicited by multiple doses.	fexofenadine	62-74	ATP binding cassette subfamily B member 1	Homo sapiens	233-247
23215684-7	2013	The difference in transporter-mediated R(+)-fexofenadine and S(-)-fexofenadine uptake was completely diminished under ATP-depleted conditions and in the presence of organic anion transporter peptide (OATP) inhibitors.	fexofenadine	61-78	solute carrier organic anion transporter family member 1A2	Homo sapiens	165-198
23215684-7	2013	The difference in transporter-mediated R(+)-fexofenadine and S(-)-fexofenadine uptake was completely diminished under ATP-depleted conditions and in the presence of organic anion transporter peptide (OATP) inhibitors.	fexofenadine	61-78	solute carrier organic anion transporter family member 1A2	Homo sapiens	200-204
22740401-7	2012	The binding pockets for two proposed inhibitors of the CD81-HCV interaction, namely, benzyl salicylate and fexofenadine, were shown to overlap the HCV and membrane interaction sites.	fexofenadine	107-119	CD81 molecule	Homo sapiens	55-59
22830293-0	2012	Enhancement of clara cell 10-kD protein (CC10) production from nasal epithelial cells by fexofenadine hydrochloride.	fexofenadine	89-115	secretoglobin family 1A member 1	Homo sapiens	41-45
22830293-3	2012	In the present study, we examined the influence of a histamine H1 receptor antagonist, fexofenadine hydrochloride (FEX) on CC10 production in vitro and in vivo.	fexofenadine	87-113	secretoglobin family 1A member 1	Homo sapiens	123-127
22830293-3	2012	In the present study, we examined the influence of a histamine H1 receptor antagonist, fexofenadine hydrochloride (FEX) on CC10 production in vitro and in vivo.	fexofenadine	115-118	histamine receptor H1	Homo sapiens	53-74
22830293-3	2012	In the present study, we examined the influence of a histamine H1 receptor antagonist, fexofenadine hydrochloride (FEX) on CC10 production in vitro and in vivo.	fexofenadine	115-118	secretoglobin family 1A member 1	Homo sapiens	123-127
21646440-2	2012	The purpose of this study was to determine the influence of Panax ginseng on CYP3A and P-gp function using the probe substrates midazolam and fexofenadine, respectively.	fexofenadine	142-154	ATP binding cassette subfamily B member 1	Homo sapiens	87-91
22198458-4	2012	Multiple-dose ketoconazole coadministration reduced the P-gp activity as shown by fexofenadine oral challenge.	fexofenadine	82-94	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
21833762-4	2012	Permeability of FEX was determined at different donor concentrations, and the effect of SDS at two concentration levels (10 and 50 muM) on FEX permeability was evaluated.	fexofenadine	139-142	latexin	Homo sapiens	131-134
21950458-1	2012	AIM: This aim of this study was to characterize the impact of the P-glycoprotein (P-gp) inducer, carbamazepine, on fexofenadine enantiomer pharmacokinetics.	fexofenadine	115-127	ATP binding cassette subfamily B member 1	Homo sapiens	66-80
21950458-1	2012	AIM: This aim of this study was to characterize the impact of the P-glycoprotein (P-gp) inducer, carbamazepine, on fexofenadine enantiomer pharmacokinetics.	fexofenadine	115-127	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
21950458-5	2012	The P-gp inducer showed a greater effect on the pharmacokinetic parameters of (S)-fexofenadine.	fexofenadine	78-94	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
22223343-7	2012	Mice given a histamine H1-receptor antagonist [fexofenadine (peripherally acting) or pyrilamine (peripherally and centrally acting)] or an irreversible HDC inhibitor (alpha-fluoromethylhistidine) displayed less PW endurance than control mice.	fexofenadine	47-59	histamine receptor H1	Mus musculus	13-34
21280267-6	2011	OATP2B1-mediated uptake of fexofenadine and midazolam was evaluated with Xenopus laevis oocyte gene-expression system.	fexofenadine	27-39	solute carrier organic anion transporter family member 2B1 L homeolog	Xenopus laevis	0-7
21933692-5	2011	GRP(18-27)-induced scratching was inhibited by the mu-opioid receptor antagonist naltrexone hydrochloride, the BB(2) bombesin receptor antagonist RC-3095, the H(1) histamine receptor antagonists fexofenadine hydrochloride and chlorpheniramine maleate, and the PAR(2) proteinase-activated receptor antagonist FSLLRY-NH(2).	fexofenadine	195-221	gastrin releasing peptide	Mus musculus	0-3
21664903-3	2011	JNJ7777120 (10 and 30 mg/kg) reduced this scratching behavior and ameliorated the skin lesions in a dose-dependent manner, whereas the histamine H(1) receptor antagonist fexofenadine had no such effect and did not reduce the inflammation score, even though dexamethasone reduced the scratching bouts.	fexofenadine	170-182	histamine receptor H1	Mus musculus	135-158
21780830-1	2011	Fexofenadine is a nonsedative antihistamine that exhibits good oral bioavailability despite its zwitterionic chemical structure and efflux by P-gp.	fexofenadine	0-12	phosphoglycolate phosphatase	Homo sapiens	142-146
21780830-5	2011	Studies with cellular models expressing single transporters showed that OATP2B1 expression stimulated uptake of fexofenadine at pH 6.0.	fexofenadine	112-124	solute carrier organic anion transporter family member 2B1	Homo sapiens	72-79
21780830-6	2011	Apical uptake of fexofenadine into Caco-2 cells was decreased by 45% by pretreatment with estrone 3-sulfate, an OATP inhibitor, at pH 6.0 but not at pH 7.4, indicating that OATP2B1 mediates apical uptake of fexofenadine into these cells.	fexofenadine	17-29	solute carrier organic anion transporter family member 1A2	Homo sapiens	112-116
21780830-6	2011	Apical uptake of fexofenadine into Caco-2 cells was decreased by 45% by pretreatment with estrone 3-sulfate, an OATP inhibitor, at pH 6.0 but not at pH 7.4, indicating that OATP2B1 mediates apical uptake of fexofenadine into these cells.	fexofenadine	17-29	solute carrier organic anion transporter family member 2B1	Homo sapiens	173-180
21780830-6	2011	Apical uptake of fexofenadine into Caco-2 cells was decreased by 45% by pretreatment with estrone 3-sulfate, an OATP inhibitor, at pH 6.0 but not at pH 7.4, indicating that OATP2B1 mediates apical uptake of fexofenadine into these cells.	fexofenadine	207-219	solute carrier organic anion transporter family member 2B1	Homo sapiens	173-180
21780830-11	2011	The results provide a novel insight into a vectorial transport system mainly consisting of apical OATP2B1 and basolateral MRP3 that may play an important role in delivering hydrophilic anionic and zwitterionic drugs such as pravastatin and fexofenadine into systemic circulation upon oral administration.	fexofenadine	240-252	solute carrier organic anion transporter family member 2B1	Homo sapiens	98-105
21780830-11	2011	The results provide a novel insight into a vectorial transport system mainly consisting of apical OATP2B1 and basolateral MRP3 that may play an important role in delivering hydrophilic anionic and zwitterionic drugs such as pravastatin and fexofenadine into systemic circulation upon oral administration.	fexofenadine	240-252	ATP binding cassette subfamily C member 3	Homo sapiens	122-126
21280267-13	2011	The uptake of fexofenadine by OATP2B1 cRNA-injected oocytes was significantly higher than that by water-injected oocytes.	fexofenadine	14-26	solute carrier organic anion transporter family member 2B1 L homeolog	Xenopus laevis	30-37
21280267-14	2011	Apple juice, but not midazolam, significantly decreased the uptake of fexofenadine by OATP2B1 cRNA-injected oocytes.	fexofenadine	70-82	solute carrier organic anion transporter family member 2B1 L homeolog	Xenopus laevis	86-93
21280267-15	2011	CONCLUSION: The results suggest that fexofenadine is a substrate of OATP2B1, and the transport function of OATP2B1 is subject to the genotype of SLCO2B1 c.1457C> T and apple juice.	fexofenadine	37-49	solute carrier organic anion transporter family member 2B1 L homeolog	Xenopus laevis	68-75
20869437-10	2010	Inhibition of Pgp by PSC-833 affected fexofenadine absorption only in distal segments resulting in AUC values comparable to the proximal data.	fexofenadine	38-50	phosphoglycolate phosphatase	Rattus norvegicus	14-17
20869437-12	2010	CONCLUSION: The study demonstrates that Pgp is responsible for a limitation of fexofenadine absorption from distal small intestine.	fexofenadine	79-91	phosphoglycolate phosphatase	Rattus norvegicus	40-43
20839930-2	2010	The area under the plasma concentration-time curve (AUC(0-24)) of S-fexofenadine, but not R-fexofenadine, was significantly lower in subjects with a SLCO2B1*1/*1 allele as compared to subjects with a *3 allele (p = 0.031).	fexofenadine	66-80	solute carrier organic anion transporter family member 2B1	Homo sapiens	149-156
20797388-1	2010	OATP1A2 and OATP2B1 are uptake transporters of the human organic anion transporting polypeptide (OATP) family with a broad substrate spectrum including several endogenous compounds as well as drugs such as the antihistaminic drug fexofenadine and HMG-CoA reductase inhibitors.	fexofenadine	230-242	solute carrier organic anion transporter family member 1A2	Homo sapiens	0-7
20797388-1	2010	OATP1A2 and OATP2B1 are uptake transporters of the human organic anion transporting polypeptide (OATP) family with a broad substrate spectrum including several endogenous compounds as well as drugs such as the antihistaminic drug fexofenadine and HMG-CoA reductase inhibitors.	fexofenadine	230-242	solute carrier organic anion transporter family member 2B1	Homo sapiens	12-19
20797388-1	2010	OATP1A2 and OATP2B1 are uptake transporters of the human organic anion transporting polypeptide (OATP) family with a broad substrate spectrum including several endogenous compounds as well as drugs such as the antihistaminic drug fexofenadine and HMG-CoA reductase inhibitors.	fexofenadine	230-242	solute carrier organic anion transporter family member 1A2	Homo sapiens	57-95
20797388-1	2010	OATP1A2 and OATP2B1 are uptake transporters of the human organic anion transporting polypeptide (OATP) family with a broad substrate spectrum including several endogenous compounds as well as drugs such as the antihistaminic drug fexofenadine and HMG-CoA reductase inhibitors.	fexofenadine	230-242	solute carrier organic anion transporter family member 1A2	Homo sapiens	0-4
20797388-7	2010	Apigenin, kaempferol, and quercetin led to a concentration-dependent decrease of the OATP1A2-mediated fexofenadine transport with IC(50) values of 4.3muM, 12.0muM, and 12.6muM, respectively.	fexofenadine	102-114	solute carrier organic anion transporter family member 1A2	Homo sapiens	85-92
21039758-2	2010	The discovery was based on an opposite to anticipated finding when assessing the possibility of grapefruit juice increasing oral fexofenadine bioavailability in humans through inhibition of intestinal MDR1-mediated efflux transport.	fexofenadine	129-141	ATP binding cassette subfamily B member 1	Homo sapiens	201-205
20839930-4	2010	The pharmacokinetic properties of S-fexofenadine are affected by a single polymorphism of SLCO2B1 in combination with several polymorphisms of ABCB1 C1236T, C3435T, and ABCC2 C-24T.	fexofenadine	34-48	solute carrier organic anion transporter family member 2B1	Homo sapiens	90-97
20839930-4	2010	The pharmacokinetic properties of S-fexofenadine are affected by a single polymorphism of SLCO2B1 in combination with several polymorphisms of ABCB1 C1236T, C3435T, and ABCC2 C-24T.	fexofenadine	34-48	ATP binding cassette subfamily B member 1	Homo sapiens	143-148
20839930-4	2010	The pharmacokinetic properties of S-fexofenadine are affected by a single polymorphism of SLCO2B1 in combination with several polymorphisms of ABCB1 C1236T, C3435T, and ABCC2 C-24T.	fexofenadine	34-48	ATP binding cassette subfamily C member 2	Homo sapiens	169-174
20839930-6	2010	These findings suggest that a combination of multiple transporters, including OATP, P-gp, and MRP2, reacts strongly to fexofenadine exposure in the small intestine and liver, resulting in different dispositions of both enantiomers.	fexofenadine	119-131	solute carrier organic anion transporter family member 1A2	Homo sapiens	78-82
20839930-6	2010	These findings suggest that a combination of multiple transporters, including OATP, P-gp, and MRP2, reacts strongly to fexofenadine exposure in the small intestine and liver, resulting in different dispositions of both enantiomers.	fexofenadine	119-131	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
20839930-6	2010	These findings suggest that a combination of multiple transporters, including OATP, P-gp, and MRP2, reacts strongly to fexofenadine exposure in the small intestine and liver, resulting in different dispositions of both enantiomers.	fexofenadine	119-131	ATP binding cassette subfamily C member 2	Homo sapiens	94-98
20863200-9	2010	This is consistent with a reduction in hepatic Oatp and/or P-gp for a high extraction ratio drug such as fexofenadine.	fexofenadine	105-117	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	59-63
21188040-1	2010	Fexofenadine is a selective histamine H(1) receptor antagonist, used for relief of the symptoms of allergy.	fexofenadine	0-12	histamine receptor H1	Homo sapiens	28-51
20306185-0	2010	Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers.	fexofenadine	51-63	ATP binding cassette subfamily B member 1	Homo sapiens	67-81
20306185-3	2010	We have assessed the possible inhibitory effects of metronidazole on P-gp-mediated drug disposition in healthy subjects using fexofenadine as a P-gp substrate.	fexofenadine	126-138	ATP binding cassette subfamily B member 1	Homo sapiens	144-148
20307657-2	2010	Fexofenadine was chosen to represent an unmetabolized transporter substrate (P-gP and OATP).	fexofenadine	0-12	phosphoglycolate phosphatase	Homo sapiens	77-81
20307657-2	2010	Fexofenadine was chosen to represent an unmetabolized transporter substrate (P-gP and OATP).	fexofenadine	0-12	solute carrier organic anion transporter family member 1A2	Homo sapiens	86-90
20214407-4	2010	Digoxin, fexofenadine, talinolol and quinidine are commonly used probe drugs for P-gp phenotyping.	fexofenadine	9-21	ATP binding cassette subfamily B member 1	Homo sapiens	81-85
19947891-3	2010	This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers.	fexofenadine	61-73	ATP binding cassette subfamily B member 1	Homo sapiens	158-172
19947891-3	2010	This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers.	fexofenadine	236-248	ATP binding cassette subfamily B member 1	Homo sapiens	158-172
19947891-7	2010	Co-administration of itraconazole and/or verapamil significantly increased the AUC(0 - 24) of both enantiomers; their influence on the P-glycoprotein-mediated transport of (S)-fexofenadine was greater than that of the (R)-enantiomer.	fexofenadine	172-188	ATP binding cassette subfamily B member 1	Homo sapiens	135-149
19947891-8	2010	However, because t(max) and t(1/2) were constant in both studies, the fexofenadine stereoselective pharmacokinetics appears to be due to P-glycoprotein efflux activity in the small intestine, which suggests that P-glycoprotein probably possesses the chiral discriminatory abilities.	fexofenadine	70-82	ATP binding cassette subfamily B member 1	Homo sapiens	137-151
19947891-8	2010	However, because t(max) and t(1/2) were constant in both studies, the fexofenadine stereoselective pharmacokinetics appears to be due to P-glycoprotein efflux activity in the small intestine, which suggests that P-glycoprotein probably possesses the chiral discriminatory abilities.	fexofenadine	70-82	ATP binding cassette subfamily B member 1	Homo sapiens	212-226
19204737-8	2009	Coculture with fexofenadine(1 microM), an MDR1 substrate known to rescue misfolding in other membrane proteins, restored cell surface expression of MDR1 G2677T/C3435T and restored resistance to block HERG by ibutilide 200 nM (98.5+/-0.98% vs 42.3+/-2.2%, P<0.001).	fexofenadine	15-27	ATP binding cassette subfamily B member 1	Homo sapiens	42-46
19652466-7	2009	Fexofenadine, a histamine H1 receptor antagonist, reduced scratching induced by histamine but not by substance P, whereas JNJ7777120, a histamine H4 receptor antagonist, significantly reduced both histamine- and substance P-induced scratching.	fexofenadine	0-12	histamine receptor H1	Homo sapiens	16-37
19703347-1	2009	OBJECTIVES: This study examined the effects of St John"s wort (Hypericum perforatum) on the disposition of fexofenadine, a substrate of P-glycoprotein/organic anion transporting polypeptide, in the isolated perfused rat liver.	fexofenadine	107-119	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	136-150
19785645-9	2009	SLCO1B1 polymorphism also affects the pharmacokinetics of many other, but not all (fluvastatin), statins and that of the antidiabetic drug repaglinide, the antihistamine fexofenadine and the endothelin A receptor antagonist atrasentan.	fexofenadine	170-182	solute carrier organic anion transporter family member 1B1	Homo sapiens	0-7
19221726-0	2009	Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.	fexofenadine	58-70	ATP binding cassette subfamily B member 1	Homo sapiens	87-101
19221726-8	2009	CONCLUSION: The results of the present study showed that short-term use of quercetin elevated the plasma concentrations of fexofenadine, probably by the inhibition of P-gp-mediated efflux in humans.	fexofenadine	123-135	ATP binding cassette subfamily B member 1	Homo sapiens	167-171
19204737-8	2009	Coculture with fexofenadine(1 microM), an MDR1 substrate known to rescue misfolding in other membrane proteins, restored cell surface expression of MDR1 G2677T/C3435T and restored resistance to block HERG by ibutilide 200 nM (98.5+/-0.98% vs 42.3+/-2.2%, P<0.001).	fexofenadine	15-27	ATP binding cassette subfamily B member 1	Homo sapiens	148-152
19204737-8	2009	Coculture with fexofenadine(1 microM), an MDR1 substrate known to rescue misfolding in other membrane proteins, restored cell surface expression of MDR1 G2677T/C3435T and restored resistance to block HERG by ibutilide 200 nM (98.5+/-0.98% vs 42.3+/-2.2%, P<0.001).	fexofenadine	15-27	potassium voltage-gated channel subfamily H member 2	Homo sapiens	200-204
19204737-9	2009	The non-synonymous MDR1 variant G2677 T (A893S) confers resistance to ibutilide block of I(Kr), which is mitigated by the C3435T polymorphism through reduced protein expression, an effect that can be restored by coculture with fexofenadine.	fexofenadine	227-239	ATP binding cassette subfamily B member 1	Homo sapiens	19-23
19552748-9	2009	CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine.	fexofenadine	88-100	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
19552748-9	2009	CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine.	fexofenadine	88-100	ATP binding cassette subfamily B member 1	Homo sapiens	194-198
19552748-0	2009	Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.	fexofenadine	32-44	ATP binding cassette subfamily B member 1	Homo sapiens	54-68
19552748-9	2009	CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine.	fexofenadine	149-161	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
19552748-1	2009	AIMS: The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate.	fexofenadine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	65-79
19552748-9	2009	CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine.	fexofenadine	149-161	ATP binding cassette subfamily B member 1	Homo sapiens	194-198
19552748-1	2009	AIMS: The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate.	fexofenadine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	81-85
19552748-1	2009	AIMS: The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate.	fexofenadine	130-142	ATP binding cassette subfamily B member 1	Homo sapiens	160-164
19552748-9	2009	CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine.	fexofenadine	252-266	ATP binding cassette subfamily B member 1	Homo sapiens	38-42
19552748-9	2009	CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine.	fexofenadine	252-266	ATP binding cassette subfamily B member 1	Homo sapiens	194-198
19232844-4	2009	CYP3A4/5 and transporters were assessed using alfentanil and fexofenadine, respectively.	fexofenadine	61-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
19114463-1	2009	P-glycoprotein (P-gp) plays an important role in determining net brain uptake of fexofenadine.	fexofenadine	81-93	phosphoglycolate phosphatase	Mus musculus	0-14
19114463-2	2009	Initial in vivo experiments with 24-h subcutaneous osmotic minipump administration demonstrated that fexofenadine brain penetration was 48-fold higher in mdr1a(-/-) mice than in mdr1a(+/+) mice.	fexofenadine	101-113	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	154-159
19114463-3	2009	In contrast, the P-gp efflux ratio at the blood-brain barrier (BBB) for fexofenadine was only approximately 4 using an in situ brain perfusion technique.	fexofenadine	72-84	phosphoglycolate phosphatase	Mus musculus	17-21
19114463-4	2009	Pharmacokinetic modeling based on the experimental results indicated that the apparent fexofenadine P-gp efflux ratio is time-dependent due to low passive permeability at the BBB.	fexofenadine	87-99	phosphoglycolate phosphatase	Mus musculus	100-104
19114463-9	2009	Taken together, these results indicate that the fexofenadine BBB P-gp efflux ratio has been underestimated previously due to the lack of complete equilibration of fexofenadine across the blood-brain interface under typical experimental paradigms.	fexofenadine	48-60	phosphoglycolate phosphatase	Mus musculus	65-69
19114463-1	2009	P-glycoprotein (P-gp) plays an important role in determining net brain uptake of fexofenadine.	fexofenadine	81-93	phosphoglycolate phosphatase	Mus musculus	16-20
19238656-8	2008	Acute and steady-state ritonavir increased the fexofenadine AUC(0-infinity) 2.8- and 1.4-fold, respectively, suggesting P-gp inhibition.	fexofenadine	47-59	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
19114463-9	2009	Taken together, these results indicate that the fexofenadine BBB P-gp efflux ratio has been underestimated previously due to the lack of complete equilibration of fexofenadine across the blood-brain interface under typical experimental paradigms.	fexofenadine	163-175	phosphoglycolate phosphatase	Mus musculus	65-69
19295235-4	2009	OBJECTIVE: We evaluated the variability of IL-16 and the effects of the antiallergic drugs fexofenadine (40 mg/kg/day) and ramatroban (30 mg/kg/day) on IL-16 in an OVA-sensitized BALB/c murine experimental allergic rhinitis model.	fexofenadine	91-103	interleukin 16	Mus musculus	152-157
19295235-8	2009	Fexofenadine and ramatroban significantly inhibited the following OVA-induced allergic features when compared to the nontreated sensitized group: sneezing, nasal rubbing, eosinophil infiltration, IL-16 expressions in nasal tissue, and serum IL-16 level.	fexofenadine	0-12	interleukin 16	Mus musculus	196-201
19295235-8	2009	Fexofenadine and ramatroban significantly inhibited the following OVA-induced allergic features when compared to the nontreated sensitized group: sneezing, nasal rubbing, eosinophil infiltration, IL-16 expressions in nasal tissue, and serum IL-16 level.	fexofenadine	0-12	interleukin 16	Mus musculus	241-246
18572335-1	2008	It has been shown that fexofenadine, a selective non-sedating histamine H(1)-receptor antagonist, is a substrate for P-glycoprotein (P-gp) and an organic anion transporting peptide (OATP).	fexofenadine	23-35	histamine receptor H 1	Rattus norvegicus	62-85
18572335-1	2008	It has been shown that fexofenadine, a selective non-sedating histamine H(1)-receptor antagonist, is a substrate for P-glycoprotein (P-gp) and an organic anion transporting peptide (OATP).	fexofenadine	23-35	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	117-131
18572335-1	2008	It has been shown that fexofenadine, a selective non-sedating histamine H(1)-receptor antagonist, is a substrate for P-glycoprotein (P-gp) and an organic anion transporting peptide (OATP).	fexofenadine	23-35	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	133-137
18572335-10	2008	Low absorption of fexofenadine in rats is attributed to potent secretory transport mediated by P-gp.	fexofenadine	18-30	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	95-99
18511651-8	2008	ABCB1 3435 C/T carriers showed increased basal P-gp activity in CD4+ and CD8+ T cells, increased R123-induced efflux activity in CD4+ T cell, and decreased fexofenadine AUC.	fexofenadine	156-168	ATP binding cassette subfamily B member 1	Homo sapiens	0-5
18294330-3	2008	WHAT THIS STUDY ADDS: This study indicates that the stereoselective pharmacokinetics of fexofenadine are due to P-gp-mediated transport and its stereoselectivity is altered by itraconazole, a an inhibitor of P-gp.	fexofenadine	88-100	ATP binding cassette subfamily B member 1	Homo sapiens	112-116
18570599-2	2008	We evaluated whether a genetic polymorphism of multi-drug resistance 1 gene (MDR1) could produce variations in pharmacokinetic and pharmacodynamic parameters of fexofenadine.	fexofenadine	161-173	ATP binding cassette subfamily B member 1	Homo sapiens	47-70
18570599-2	2008	We evaluated whether a genetic polymorphism of multi-drug resistance 1 gene (MDR1) could produce variations in pharmacokinetic and pharmacodynamic parameters of fexofenadine.	fexofenadine	161-173	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
18294330-3	2008	WHAT THIS STUDY ADDS: This study indicates that the stereoselective pharmacokinetics of fexofenadine are due to P-gp-mediated transport and its stereoselectivity is altered by itraconazole, a an inhibitor of P-gp.	fexofenadine	88-100	ATP binding cassette subfamily B member 1	Homo sapiens	208-212
18294330-4	2008	AIMS: The aim of this study was to determine the inhibitory effect of itraconazole, a P-glycoprotein (P-gp) inhibitor, on the stereoselective pharmacokinetics of fexofenadine.	fexofenadine	162-174	ATP binding cassette subfamily B member 1	Homo sapiens	86-100
18294330-4	2008	AIMS: The aim of this study was to determine the inhibitory effect of itraconazole, a P-glycoprotein (P-gp) inhibitor, on the stereoselective pharmacokinetics of fexofenadine.	fexofenadine	162-174	ATP binding cassette subfamily B member 1	Homo sapiens	102-106
18294330-11	2008	CONCLUSIONS: This study indicates that the stereoselective pharmacokinetics of fexofenadine are due to P-gp-mediated transport and its stereoselectivity is altered by itraconazole, a P-gp inhibitor.	fexofenadine	79-91	ATP binding cassette subfamily B member 1	Homo sapiens	103-107
18294330-11	2008	CONCLUSIONS: This study indicates that the stereoselective pharmacokinetics of fexofenadine are due to P-gp-mediated transport and its stereoselectivity is altered by itraconazole, a P-gp inhibitor.	fexofenadine	79-91	ATP binding cassette subfamily B member 1	Homo sapiens	183-187
18276836-0	2008	Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers.	fexofenadine	115-127	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	Mus musculus	22-69
18276836-0	2008	Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers.	fexofenadine	115-127	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	74-78
18276836-8	2008	In Abcc2(-/-)/Abcc3(-/-) double-knockout mice, fexofenadine biliary excretion was impaired, but perfusate recovery was similar to that in wild-type mice and more than 2-fold higher than that in Abcc3(-/-) mice, presumably due to compensatory basolateral transport mechanism(s).	fexofenadine	47-59	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	3-8
18276836-4	2008	Recently, we showed that in mice fexofenadine is excreted into bile primarily by multidrug resistance-associated protein (Mrp) 2 (Abcc2).	fexofenadine	33-45	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	81-128
18299336-7	2008	This result suggests that P-gp limits the intestinal absorption of fexofenadine in dogs.	fexofenadine	67-79	PGP	Canis lupus familiaris	26-30
18276836-4	2008	Recently, we showed that in mice fexofenadine is excreted into bile primarily by multidrug resistance-associated protein (Mrp) 2 (Abcc2).	fexofenadine	33-45	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	130-135
18276836-5	2008	In the present study, the roles of Mrp3 (Abcc3) and Mrp4 (Abcc4) in the hepatobiliary disposition of fexofenadine were examined in knockout mice using in situ liver perfusion.	fexofenadine	101-113	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	Mus musculus	35-39
18276836-5	2008	In the present study, the roles of Mrp3 (Abcc3) and Mrp4 (Abcc4) in the hepatobiliary disposition of fexofenadine were examined in knockout mice using in situ liver perfusion.	fexofenadine	101-113	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	52-56
18276836-5	2008	In the present study, the roles of Mrp3 (Abcc3) and Mrp4 (Abcc4) in the hepatobiliary disposition of fexofenadine were examined in knockout mice using in situ liver perfusion.	fexofenadine	101-113	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	58-63
18276836-6	2008	Compared with that in wild-type mice, basolateral excretion of fexofenadine was impaired, resulting in a approximately 50% decrease in perfusate recovery in Abcc3(-/-) mice; in contrast, fexofenadine hepatobiliary disposition was unaltered in Abcc4(-/-) mice.	fexofenadine	63-75	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	Mus musculus	157-162
18276836-6	2008	Compared with that in wild-type mice, basolateral excretion of fexofenadine was impaired, resulting in a approximately 50% decrease in perfusate recovery in Abcc3(-/-) mice; in contrast, fexofenadine hepatobiliary disposition was unaltered in Abcc4(-/-) mice.	fexofenadine	63-75	ATP-binding cassette, sub-family C (CFTR/MRP), member 4	Mus musculus	243-248
18276836-7	2008	As expected, in Abcc2(-/-) mice, fexofenadine was redirected from the canalicular to the basolateral membrane for excretion.	fexofenadine	33-45	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	16-21
17910814-1	2007	The aim of this study was to examine the effect of fexofenadine hydrochloride (FEX), a histamine H1-receptor antagonist, on nitric oxide (NO) production in-vitro and in-vivo.	fexofenadine	51-77	histamine receptor H1	Mus musculus	87-108
18180276-6	2008	Vectorial basal-to-apical transport of FEX was observed in double transfectants expressing OATP1B1/multidrug resistance-associated protein 2 (MRP2) and OATP1B3/MRP2, suggesting that OATP1B1 as well as OATP1B3 is involved in the hepatic uptake of FEX and that MRP2 can recognize FEX as a substrate.	fexofenadine	39-42	ATP binding cassette subfamily C member 2	Homo sapiens	91-140
18180276-6	2008	Vectorial basal-to-apical transport of FEX was observed in double transfectants expressing OATP1B1/multidrug resistance-associated protein 2 (MRP2) and OATP1B3/MRP2, suggesting that OATP1B1 as well as OATP1B3 is involved in the hepatic uptake of FEX and that MRP2 can recognize FEX as a substrate.	fexofenadine	39-42	ATP binding cassette subfamily C member 2	Homo sapiens	142-146
18180276-6	2008	Vectorial basal-to-apical transport of FEX was observed in double transfectants expressing OATP1B1/multidrug resistance-associated protein 2 (MRP2) and OATP1B3/MRP2, suggesting that OATP1B1 as well as OATP1B3 is involved in the hepatic uptake of FEX and that MRP2 can recognize FEX as a substrate.	fexofenadine	39-42	solute carrier organic anion transporter family member 1B3	Homo sapiens	152-159
18180276-6	2008	Vectorial basal-to-apical transport of FEX was observed in double transfectants expressing OATP1B1/multidrug resistance-associated protein 2 (MRP2) and OATP1B3/MRP2, suggesting that OATP1B1 as well as OATP1B3 is involved in the hepatic uptake of FEX and that MRP2 can recognize FEX as a substrate.	fexofenadine	39-42	ATP binding cassette subfamily C member 2	Homo sapiens	160-164
18180276-6	2008	Vectorial basal-to-apical transport of FEX was observed in double transfectants expressing OATP1B1/multidrug resistance-associated protein 2 (MRP2) and OATP1B3/MRP2, suggesting that OATP1B1 as well as OATP1B3 is involved in the hepatic uptake of FEX and that MRP2 can recognize FEX as a substrate.	fexofenadine	39-42	solute carrier organic anion transporter family member 1B1	Homo sapiens	91-98
18180276-6	2008	Vectorial basal-to-apical transport of FEX was observed in double transfectants expressing OATP1B1/multidrug resistance-associated protein 2 (MRP2) and OATP1B3/MRP2, suggesting that OATP1B1 as well as OATP1B3 is involved in the hepatic uptake of FEX and that MRP2 can recognize FEX as a substrate.	fexofenadine	39-42	solute carrier organic anion transporter family member 1B3	Homo sapiens	201-208
18180276-6	2008	Vectorial basal-to-apical transport of FEX was observed in double transfectants expressing OATP1B1/multidrug resistance-associated protein 2 (MRP2) and OATP1B3/MRP2, suggesting that OATP1B1 as well as OATP1B3 is involved in the hepatic uptake of FEX and that MRP2 can recognize FEX as a substrate.	fexofenadine	39-42	ATP binding cassette subfamily C member 2	Homo sapiens	160-164
18180276-7	2008	The inhibitory effects of compounds on FEX uptake in OATP1B3-expressing HEK293 cells were investigated, and the maximal degree of increase in plasma AUC of FEX by drug interaction in clinical situations was estimated.	fexofenadine	39-42	solute carrier organic anion transporter family member 1B3	Homo sapiens	53-60
17951087-3	2008	The number of citric-acid-induced coughs in sensitized guinea pigs was dose-dependently and significantly reduced to the level in non-sensitized guinea pigs when animals were pretreated with fexofenadine, a selective histamine H1 receptor antagonist, 60min before citric acid inhalation.	fexofenadine	191-203	histamine H1 receptor	Cavia porcellus	217-238
17913796-0	2008	Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice.	fexofenadine	96-108	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	0-41
17913796-1	2008	Previous studies implicated P-glycoprotein (P-gp) as the major transport protein responsible for the biliary excretion of fexofenadine (FEX).	fexofenadine	122-134	phosphoglycolate phosphatase	Mus musculus	28-42
17913796-1	2008	Previous studies implicated P-glycoprotein (P-gp) as the major transport protein responsible for the biliary excretion of fexofenadine (FEX).	fexofenadine	122-134	phosphoglycolate phosphatase	Mus musculus	44-48
17913796-1	2008	Previous studies implicated P-glycoprotein (P-gp) as the major transport protein responsible for the biliary excretion of fexofenadine (FEX).	fexofenadine	136-139	phosphoglycolate phosphatase	Mus musculus	28-42
17913796-1	2008	Previous studies implicated P-glycoprotein (P-gp) as the major transport protein responsible for the biliary excretion of fexofenadine (FEX).	fexofenadine	136-139	phosphoglycolate phosphatase	Mus musculus	44-48
17910814-1	2007	The aim of this study was to examine the effect of fexofenadine hydrochloride (FEX), a histamine H1-receptor antagonist, on nitric oxide (NO) production in-vitro and in-vivo.	fexofenadine	79-82	histamine receptor H1	Mus musculus	87-108
17215845-8	2007	However, among OATP transporters, only OATP1A2 was capable of fexofenadine uptake when assessed in vitro.	fexofenadine	62-74	solute carrier organic anion transporter family member 1A2	Homo sapiens	39-46
17230498-1	2007	Fexofenadine, a substrate of P-glycoprotein and an organic anion transporter polypeptide, is commonly used to assess P-glycoprotein activity in vivo.	fexofenadine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	29-43
17230498-1	2007	Fexofenadine, a substrate of P-glycoprotein and an organic anion transporter polypeptide, is commonly used to assess P-glycoprotein activity in vivo.	fexofenadine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	117-131
17230498-8	2007	On the other hand, the stereoselective metabolism of fexofenadine using recombinant CYP3A4 was investigated; however, fexofenadine enantiomers were not metabolized by CYP3A4.	fexofenadine	53-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
17230498-8	2007	On the other hand, the stereoselective metabolism of fexofenadine using recombinant CYP3A4 was investigated; however, fexofenadine enantiomers were not metabolized by CYP3A4.	fexofenadine	118-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90
17230498-9	2007	Fexofenadine is transported by both P-glycoprotein and OATP and is not metabolized by intestinal CYP3A.	fexofenadine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	36-50
17230498-9	2007	Fexofenadine is transported by both P-glycoprotein and OATP and is not metabolized by intestinal CYP3A.	fexofenadine	0-12	solute carrier organic anion transporter family member 1A2	Homo sapiens	55-59
17230498-10	2007	Our findings suggest that the affinity of P-glycoprotein for S(-)-fexofenadine is greater than its affinity for the R(+)-enantiomer.	fexofenadine	62-78	ATP binding cassette subfamily B member 1	Homo sapiens	42-56
17215845-12	2007	OATP1A2 is likely the key intestinal uptake transporter for fexofenadine absorption whose inhibition results in the grapefruit juice effect.	fexofenadine	60-72	solute carrier organic anion transporter family member 1A2	Homo sapiens	0-7
17133778-1	2006	Fexofenadine, a histamine H1-receptor antagonist, is approved for the treatment of pruritus associated with atopic dermatitis.	fexofenadine	0-12	histamine receptor H1	Mus musculus	16-37
17767395-1	2007	Fexofenadine, an active metabolite of the second-generation histamine H1 receptor antagonist (antihistamine) terfenadine, does not have the disadvantage of QT prolongation.	fexofenadine	0-12	histamine receptor H1	Homo sapiens	60-81
17080426-6	2007	However, the symmetric transport of fexofenadine.HCl in this NHBE cell monolayers study seems to be due to the low expression of P-gp transporter and/or to its saturation with high concentration of fexofenadine.HCl.	fexofenadine	36-48	phosphoglycolate phosphatase	Homo sapiens	129-133
17323859-5	2007	RESULTS: RT-PCR revealed that IL-12-induced expression of IFN-gamma was partially suppressed by loratadine and fexofenadine and that all 4 agents tested inhibited IL-4-induced expression of IL-5.	fexofenadine	111-123	interferon gamma	Homo sapiens	58-67
17323859-6	2007	ELISA demonstrated that IL-12-induced IFN-gamma production was significantly suppressed by cetirizine and fexofenadine and IL-4-induced IL-5 production was downregulated by three agents with the exception of cetirizine.	fexofenadine	106-118	interferon gamma	Homo sapiens	38-47
16935279-3	2006	This histamine-induced increase in the number of citric acid-induced coughs was dose dependently and significantly reduced when animals were pretreated with fexofenadine, a histamine H1 receptor antagonist.	fexofenadine	157-169	histamine H1 receptor	Cavia porcellus	173-194
17133778-4	2006	Compared with group N, group S mice showed significantly greater scratching frequency, and plasma histamine and eotaxin concentrations; these three variables were significantly lower in group S + F(0-10) than in group S. Scratching frequency increased when fexofenadine was discontinued.	fexofenadine	257-269	chemokine (C-C motif) ligand 11	Mus musculus	112-119
16964701-3	2006	Between them, polymorphisms of MDR1 gene coding trans-membrane transport glicoprotein P-gp have been reported to affect the outcome of therapy, and was studied for different drugs-digoxin, fexofenadine, etoposid, vincristine, vinblastine, athracyclines and taxans.	fexofenadine	189-201	ATP binding cassette subfamily B member 1	Homo sapiens	31-35
16767419-3	2006	One hypothesis suggests that this is due to fexofenadine producing an increase in dopamine levels by blocking the dopamine transporter.	fexofenadine	44-56	solute carrier family 6 member 3	Homo sapiens	114-134
16767419-4	2006	OBJECTIVE: In this study, it was investigated whether a high dose of fexofenadine blocks the dopamine transporter in the striatum.	fexofenadine	69-81	solute carrier family 6 member 3	Homo sapiens	93-113
16850393-6	2006	Fexofenadine is a substrate for Pgp, Oatp1, Oatp2, and Oatp3.	fexofenadine	0-12	phosphoglycolate phosphatase	Rattus norvegicus	32-35
16850393-6	2006	Fexofenadine is a substrate for Pgp, Oatp1, Oatp2, and Oatp3.	fexofenadine	0-12	solute carrier organic anion transporter family, member 1a1	Rattus norvegicus	37-42
16850393-6	2006	Fexofenadine is a substrate for Pgp, Oatp1, Oatp2, and Oatp3.	fexofenadine	0-12	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	44-49
16850393-6	2006	Fexofenadine is a substrate for Pgp, Oatp1, Oatp2, and Oatp3.	fexofenadine	0-12	solute carrier organic anion transporter family, member 1A5	Rattus norvegicus	55-60
16850393-7	2006	BA appears to preferentially inhibit Oatp3 over Pgp in the intestine, leading to the decreased oral absorption of fexofenadine.	fexofenadine	114-126	solute carrier organic anion transporter family, member 1A5	Rattus norvegicus	37-42
16850393-7	2006	BA appears to preferentially inhibit Oatp3 over Pgp in the intestine, leading to the decreased oral absorption of fexofenadine.	fexofenadine	114-126	phosphoglycolate phosphatase	Rattus norvegicus	48-51
16946558-6	2006	Furthermore, uptake of fexofenadine by Xenopus oocytes expressing rat oatp3 was significantly greater than that by water-injected oocytes, and the affinity of oatp3 for fexofenadine (Km) was about 60 microM, which is comparable with the value obtained by the Ussing chamber method using rat intestinal tissues.	fexofenadine	23-35	solute carrier organic anion transporter family, member 1A5	Rattus norvegicus	70-75
16946558-6	2006	Furthermore, uptake of fexofenadine by Xenopus oocytes expressing rat oatp3 was significantly greater than that by water-injected oocytes, and the affinity of oatp3 for fexofenadine (Km) was about 60 microM, which is comparable with the value obtained by the Ussing chamber method using rat intestinal tissues.	fexofenadine	23-35	solute carrier organic anion transporter family, member 1A5	Rattus norvegicus	159-164
16946558-6	2006	Furthermore, uptake of fexofenadine by Xenopus oocytes expressing rat oatp3 was significantly greater than that by water-injected oocytes, and the affinity of oatp3 for fexofenadine (Km) was about 60 microM, which is comparable with the value obtained by the Ussing chamber method using rat intestinal tissues.	fexofenadine	169-181	solute carrier organic anion transporter family, member 1A5	Rattus norvegicus	159-164
16946558-7	2006	These results indicate that oatp3 plays a role as an influx transporter in the intestinal absorption of fexofenadine in rats.	fexofenadine	104-116	solute carrier organic anion transporter family, member 1A5	Rattus norvegicus	28-33
16174671-10	2006	P1 and P3 latency were affected by Treatment x Workload and Treatment respectively and indicated faster attentional and information processing latencies following fexofenadine treatment.	fexofenadine	163-175	crystallin gamma F, pseudogene	Homo sapiens	0-9
16964701-3	2006	Between them, polymorphisms of MDR1 gene coding trans-membrane transport glicoprotein P-gp have been reported to affect the outcome of therapy, and was studied for different drugs-digoxin, fexofenadine, etoposid, vincristine, vinblastine, athracyclines and taxans.	fexofenadine	189-201	phosphoglycolate phosphatase	Homo sapiens	86-90
16455804-0	2006	Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid.	fexofenadine	90-102	solute carrier family 22 member 8	Homo sapiens	14-18
16625658-10	2006	To further study the utility of ABT, the antihistamine fexofenadine (Fex), which is not significantly metabolized and is a substrate for the uptake and efflux transporters, OATP and P-gp, was tested in rat.	fexofenadine	55-67	phosphoglycolate phosphatase	Rattus norvegicus	182-186
16625658-10	2006	To further study the utility of ABT, the antihistamine fexofenadine (Fex), which is not significantly metabolized and is a substrate for the uptake and efflux transporters, OATP and P-gp, was tested in rat.	fexofenadine	69-72	phosphoglycolate phosphatase	Rattus norvegicus	182-186
16455807-11	2006	Such intestinal absorption property of bepotastine is distinctly different from the low membrane-permeable P-gp substrate fexofenadine.	fexofenadine	122-134	phosphoglycolate phosphatase	Mus musculus	107-111
16455804-4	2006	The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2).	fexofenadine	14-26	solute carrier family 22 member 6	Homo sapiens	75-102
16455804-4	2006	The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2).	fexofenadine	14-26	solute carrier family 22 member 2	Homo sapiens	185-189
16455804-4	2006	The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2).	fexofenadine	14-26	solute carrier family 22 member 2	Homo sapiens	190-197
16455804-5	2006	Only hOAT3-HEK showed a significantly greater accumulation of fexofenadine than that in vector-HEK, which was saturable with K(m) and V(max) values of 70.2 microM and 120 pmol/min/mg protein, respectively.	fexofenadine	62-74	solute carrier family 22 member 8	Homo sapiens	5-10
16455804-4	2006	The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2).	fexofenadine	14-26	solute carrier family 22 member 6	Homo sapiens	104-108
16455804-6	2006	Inhibition potency of probenecid for the uptake of fexofenadine was compared between hOAT3 and organic anion-transporting peptide 1B3 (hOATP1B3), a transporter responsible for the hepatic uptake of fexofenadine (Drug Metab Dispos 33:1477-1481, 2005).	fexofenadine	198-210	solute carrier family 22 member 8	Homo sapiens	85-133
16455804-6	2006	Inhibition potency of probenecid for the uptake of fexofenadine was compared between hOAT3 and organic anion-transporting peptide 1B3 (hOATP1B3), a transporter responsible for the hepatic uptake of fexofenadine (Drug Metab Dispos 33:1477-1481, 2005).	fexofenadine	198-210	solute carrier organic anion transporter family member 1B3	Homo sapiens	135-143
16455804-4	2006	The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2).	fexofenadine	14-26	solute carrier family 22 member 6	Homo sapiens	109-116
16455804-9	2006	These results suggest that the renal drug-drug interaction between fexofenadine and probenecid is probably explained by an inhibition of the renal uptake of fexofenadine via hOAT3, at least in part.	fexofenadine	67-79	solute carrier family 22 member 8	Homo sapiens	174-179
16455804-4	2006	The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2).	fexofenadine	14-26	solute carrier family 22 member 7	Homo sapiens	119-123
16455804-9	2006	These results suggest that the renal drug-drug interaction between fexofenadine and probenecid is probably explained by an inhibition of the renal uptake of fexofenadine via hOAT3, at least in part.	fexofenadine	157-169	solute carrier family 22 member 8	Homo sapiens	174-179
16455804-4	2006	The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2).	fexofenadine	14-26	solute carrier family 22 member 7	Homo sapiens	125-132
16455804-4	2006	The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2).	fexofenadine	14-26	solute carrier family 22 member 8	Homo sapiens	135-139
16455804-4	2006	The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2).	fexofenadine	14-26	solute carrier family 22 member 8	Homo sapiens	141-148
16455804-4	2006	The uptake of fexofenadine was determined in HEK293 cells expressing human organic anion transporter 1 (OAT1/SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), and organic cation transporter 2 (OCT2/SLC22A2).	fexofenadine	14-26	solute carrier family 22 member 2	Homo sapiens	155-183
16270723-0	2005	The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils.	fexofenadine	14-26	intercellular adhesion molecule 1	Homo sapiens	44-77
17016062-6	2006	RESULTS: High concentrations of FEX (10(-3) mol/l) significantly inhibited arachidonic acid-mediated ovine COX-1 activity, but low concentrations had no effect.	fexofenadine	32-35	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	107-112
17016062-8	2006	The inhibition of COX-2 activity by FEX was similar to that seen with the selective COX-2 inhibitor, DuP-679.	fexofenadine	36-39	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	18-23
17016062-11	2006	CONCLUSION: FEX showed selective arachidonic acid-mediated COX-2 inhibitory enzyme activity, which differed markedly from the COX inhibitory enzyme activity of LOR.	fexofenadine	12-15	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	59-64
17016062-12	2006	This selective COX-2 inhibitor activity by FEX may contribute to its anti-inflammatory properties in relieving nasal congestion in allergic rhinitis.	fexofenadine	43-46	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	15-20
16014768-0	2005	Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans.	fexofenadine	107-119	solute carrier organic anion transporter family member 1A2	Homo sapiens	16-20
16014768-0	2005	Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans.	fexofenadine	107-119	solute carrier organic anion transporter family member 1A2	Homo sapiens	22-60
16014768-12	2005	In conclusion, this is, to our knowledge, the first demonstration that OATP1B3 is thought to be a major transporter involved in hepatic uptake of FEX in humans.	fexofenadine	146-149	solute carrier organic anion transporter family member 1B3	Homo sapiens	71-78
17016062-0	2006	New evidence of H1-receptor independent COX-2 inhibition by fexofenadine HCl in vitro.	fexofenadine	60-76	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	40-45
17016062-3	2006	METHODS: The effects of two antihistamines, FEX and loratadine (LOR), were investigated on cyclooxygenase (COX)-1 and -2 enzymes in vitro.	fexofenadine	44-47	prostaglandin-endoperoxide synthase 1	Homo sapiens	91-120
16572735-0	2005	The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis.	fexofenadine	33-49	BH3 interacting domain death agonist	Homo sapiens	50-53
16572735-13	2005	Fexofenadine 30 mg bid is effective in reducing the total symptom score of allergic rhinitis including blocked nose and is generally well tolerated.	fexofenadine	0-12	BH3 interacting domain death agonist	Homo sapiens	19-22
16361727-6	2005	In contrast, cetiridine and fexofenadine unexpectedly increased the substance P level.	fexofenadine	28-40	tachykinin precursor 1	Homo sapiens	68-79
16270723-3	2005	To assess the possible anti-inflammatory activity of fexofenadine, a selective H1-receptor antagonist, we evaluated its capacity to modulate the expression of adhesion molecules leukocyte function-associated antigen (LFA) 1 and intracellular adhesion molecule (ICAM) 1 on eosinophil surface and to induce apoptosis of eosinophils.	fexofenadine	53-65	integrin subunit alpha L	Homo sapiens	178-223
16270723-3	2005	To assess the possible anti-inflammatory activity of fexofenadine, a selective H1-receptor antagonist, we evaluated its capacity to modulate the expression of adhesion molecules leukocyte function-associated antigen (LFA) 1 and intracellular adhesion molecule (ICAM) 1 on eosinophil surface and to induce apoptosis of eosinophils.	fexofenadine	53-65	intercellular adhesion molecule 1	Homo sapiens	228-268
16270723-5	2005	To evaluate apoptosis of eosinophils, cells stimulated with interleukin-5, in the presence of different concentrations of fexofenadine, have been incubated with a phosphatidylserine-binding protein (annexin V) fluorescein isothiocyanate conjugated and then analyzed by flow cytometry.	fexofenadine	122-134	interleukin 5	Homo sapiens	60-73
16270723-7	2005	In this study, fexofenadine did not cause any significant changes in the expression of LFA-1 but was shown to be able to inhibit the expression of ICAM-1 at concentrations between 10(-3) and 10(-4) M. Moreover, concentrations of fexofenadine from 10(-3) to 6 x 10(-4) M induced a significant increment in the percentage of apoptotic cells.	fexofenadine	15-27	intercellular adhesion molecule 1	Homo sapiens	147-153
16270723-7	2005	In this study, fexofenadine did not cause any significant changes in the expression of LFA-1 but was shown to be able to inhibit the expression of ICAM-1 at concentrations between 10(-3) and 10(-4) M. Moreover, concentrations of fexofenadine from 10(-3) to 6 x 10(-4) M induced a significant increment in the percentage of apoptotic cells.	fexofenadine	229-241	intercellular adhesion molecule 1	Homo sapiens	147-153
16270723-8	2005	Our findings indicate the possibility of obtaining relevant anti-inflammatory pharmacologic effects, other than antihistamine activity, by fexofenadine, such as inhibition of ICAM-1 expression and induction of eosinophil apoptosis.	fexofenadine	139-151	intercellular adhesion molecule 1	Homo sapiens	175-181
15842561-0	2005	Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1).	fexofenadine	0-12	solute carrier organic anion transporter family member 1B1	Homo sapiens	72-79
15821041-0	2005	P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.	fexofenadine	51-63	phosphoglycolate phosphatase	Mus musculus	0-14
15821041-6	2005	In addition, the steady-state brain-to-plasma concentration ratio of fexofenadine was approximately 3-fold higher in Mdr1a/1b P-gp knockout mice than in wild-type mice.	fexofenadine	69-81	ATP-binding cassette, sub-family B (MDR/TAP), member 1A	Mus musculus	117-122
15821041-6	2005	In addition, the steady-state brain-to-plasma concentration ratio of fexofenadine was approximately 3-fold higher in Mdr1a/1b P-gp knockout mice than in wild-type mice.	fexofenadine	69-81	phosphoglycolate phosphatase	Mus musculus	126-130
15821041-9	2005	These results suggest that the biliary excretion of fexofenadine is mediated by unknown transporters distinct from P-gp, Mrp2, and Bcrp.	fexofenadine	52-64	ATP-binding cassette, sub-family C (CFTR/MRP), member 2	Mus musculus	121-125
15842561-0	2005	Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1).	fexofenadine	0-12	solute carrier organic anion transporter family member 1B1	Homo sapiens	95-102
15601808-5	2005	Fexofenadine is a P-gp probe but not a CYP3A substrate.	fexofenadine	0-12	phosphoglycolate phosphatase	Homo sapiens	18-22
15570603-1	2005	Fexofenadine has been identified as a substrate for both the efflux transporter, P-glycoprotein (P-gp), as well as the influx transporter, organic anion transporting polypeptide (OATP).	fexofenadine	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	81-95
15570603-1	2005	Fexofenadine has been identified as a substrate for both the efflux transporter, P-glycoprotein (P-gp), as well as the influx transporter, organic anion transporting polypeptide (OATP).	fexofenadine	0-12	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	97-101
15570603-1	2005	Fexofenadine has been identified as a substrate for both the efflux transporter, P-glycoprotein (P-gp), as well as the influx transporter, organic anion transporting polypeptide (OATP).	fexofenadine	0-12	solute carrier organic anion transporter family member 1A2	Homo sapiens	179-183
15570603-2	2005	Clinical studies in humans showed that fruit juices reduced the oral bioavailability of fexofenadine by preferentially inhibiting OATP over P-gp.	fexofenadine	88-100	solute carrier organic anion transporter family member 1A2	Homo sapiens	130-134
15570603-2	2005	Clinical studies in humans showed that fruit juices reduced the oral bioavailability of fexofenadine by preferentially inhibiting OATP over P-gp.	fexofenadine	88-100	phosphoglycolate phosphatase	Homo sapiens	140-144
15570603-5	2005	Coadministration of fexofenadine with ketoconazole, a P-gp inhibitor, increased the oral exposure of fexofenadine by 187%.	fexofenadine	20-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	54-58
15570603-5	2005	Coadministration of fexofenadine with ketoconazole, a P-gp inhibitor, increased the oral exposure of fexofenadine by 187%.	fexofenadine	101-113	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	54-58
15601808-6	2005	This investigation tested the hypothesis that alfentanil and fexofenadine could be administered in combination to probe first-pass CYP3A and P-gp activities in humans.	fexofenadine	61-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-136
15601808-6	2005	This investigation tested the hypothesis that alfentanil and fexofenadine could be administered in combination to probe first-pass CYP3A and P-gp activities in humans.	fexofenadine	61-73	phosphoglycolate phosphatase	Homo sapiens	141-145
15601808-17	2005	Alfentanil and fexofenadine in combination appear to be a useful probe for evaluating both first-pass CYP3A and P-gp activities in humans.	fexofenadine	15-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	102-107
15601808-17	2005	Alfentanil and fexofenadine in combination appear to be a useful probe for evaluating both first-pass CYP3A and P-gp activities in humans.	fexofenadine	15-27	phosphoglycolate phosphatase	Homo sapiens	112-116
15663564-4	2004	OBJECTIVE: We evaluated whether fexofenadine hydrochloride (FEX), the carboxylic acid metabolite of terfenadine with selective H(1)-receptor antagonist activity, could inhibit MMP production from nasal fibroblasts (NFs) in response to TNF-alpha stimulation in vitro.	fexofenadine	32-58	tumor necrosis factor	Homo sapiens	235-244
15663564-4	2004	OBJECTIVE: We evaluated whether fexofenadine hydrochloride (FEX), the carboxylic acid metabolite of terfenadine with selective H(1)-receptor antagonist activity, could inhibit MMP production from nasal fibroblasts (NFs) in response to TNF-alpha stimulation in vitro.	fexofenadine	60-63	tumor necrosis factor	Homo sapiens	235-244
15663564-12	2004	FEX also inhibited MMP mRNA expression and NF-kappa B activation in PF and MF after TNF-alpha stimulation.	fexofenadine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	43-53
15663564-12	2004	FEX also inhibited MMP mRNA expression and NF-kappa B activation in PF and MF after TNF-alpha stimulation.	fexofenadine	0-3	tumor necrosis factor	Homo sapiens	84-93
15037214-12	2004	In CBF1 mice injected with serum from NC/Nga mice with high IgE levels, the decrease in rectal temperature was suppressed by single administration of fexofenadine HCl (10 and 20 mg/kg; p<0.01 and p<0.001, respectively).	fexofenadine	150-166	recombination signal binding protein for immunoglobulin kappa J region	Mus musculus	3-7
15331914-6	2004	In contrast, acrivastine and fexofenadine had low brain-to-plasma ratios of 0.072 +/- 0.014 and 0.018 + 0.002, consistent with low passive membrane permeability for both compounds (16.2 and 66 nm/s, respectively) and Pgp efflux.	fexofenadine	29-41	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	217-220
15359574-7	2004	All four P-gp inhibitors had a strong, concentration-dependent effect on the Papp of fexofenadine in both directions, with GF 120918 being the most specific among them.	fexofenadine	85-97	ATP binding cassette subfamily B member 1	Homo sapiens	9-13
15359574-8	2004	The IC50 of verapamil was 8.44 microM on the P-gp-mediated secretion of fexofenadine.	fexofenadine	72-84	ATP binding cassette subfamily B member 1	Homo sapiens	45-49
15359574-10	2004	CONCLUSIONS: This study clearly indicates that P-gp was the main transport protein of fexofenadine in the Caco-2 model.	fexofenadine	86-98	ATP binding cassette subfamily B member 1	Homo sapiens	47-51
14976396-0	2004	Suppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro.	fexofenadine	24-50	C-C motif chemokine ligand 17	Homo sapiens	54-96
14976396-3	2004	The aim of this study is to examine the influence of fexofenadine hydrochloride (FEX), an H1-receptor antagonist, on TARC production from human peripheral blood leukocytes (PBL) using an in vitro cell culture technique.	fexofenadine	53-79	C-C motif chemokine ligand 17	Homo sapiens	117-121
14976396-3	2004	The aim of this study is to examine the influence of fexofenadine hydrochloride (FEX), an H1-receptor antagonist, on TARC production from human peripheral blood leukocytes (PBL) using an in vitro cell culture technique.	fexofenadine	81-84	C-C motif chemokine ligand 17	Homo sapiens	117-121
15536457-0	2004	A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.	fexofenadine	48-60	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
15536457-3	2004	This study was performed to clarify the effects of major MDR1 gene polymorphisms, including a variant A allele in exon 21, on fexofenadine pharmacokinetics.	fexofenadine	126-138	ATP binding cassette subfamily B member 1	Homo sapiens	57-61
15536457-5	2004	A single oral dose of 180 mg fexofenadine hydrochloride was administered to 33 healthy Korean male volunteers, who were divided into 6 groups based on the MDR1 genotype for the G2677T/A polymorphism in exon 21 and the C3435T polymorphism in exon 26.	fexofenadine	29-55	ATP binding cassette subfamily B member 1	Homo sapiens	155-159
15352500-0	2004	A novel membrane sensor for histamine H1-receptor antagonist "fexofenadine".	fexofenadine	62-74	histamine receptor H1	Homo sapiens	28-49
15312146-11	2004	Fexofenadine is a P-glycoprotein (P-gp) substrate and P-gp is certainly involved both in the poor brain penetration by the compound and, at least partially, in a number of observed drug interactions.	fexofenadine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	18-32
15312146-11	2004	Fexofenadine is a P-glycoprotein (P-gp) substrate and P-gp is certainly involved both in the poor brain penetration by the compound and, at least partially, in a number of observed drug interactions.	fexofenadine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	34-38
15125696-0	2004	Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates.	fexofenadine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	76-90
15125696-2	2004	Several studies have shown P-glycoprotein is involved in the absorption and excretion of fexofenadine.	fexofenadine	89-101	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
15125696-8	2004	In addition, the effect of fexofenadine on P-glycoprotein function was examined by flow cytometry using rhodamine 123 and CD56-positive lymphocytes.	fexofenadine	27-39	ATP binding cassette subfamily B member 1	Homo sapiens	43-57
15180356-7	2004	Fexofenadine significantly inhibited IL6 (p < 0.004) and TNFalpha (p < 0.004) levels in comparison with placebo.	fexofenadine	0-12	interleukin 6	Homo sapiens	37-40
15180356-7	2004	Fexofenadine significantly inhibited IL6 (p < 0.004) and TNFalpha (p < 0.004) levels in comparison with placebo.	fexofenadine	0-12	tumor necrosis factor	Homo sapiens	60-68
15180356-9	2004	Fexofenadine reduces TNFalpha and IL6 levels only.	fexofenadine	0-12	tumor necrosis factor	Homo sapiens	21-29
15180356-9	2004	Fexofenadine reduces TNFalpha and IL6 levels only.	fexofenadine	0-12	interleukin 6	Homo sapiens	34-37
15217301-6	2004	With regard to the variability, polymorphisms of the MDR1 gene have recently been reported to be associated with alterations in disposition kinetics and interaction profiles of clinically useful drugs, including digoxin, fexofenadine, ciclosporin and talinolol.	fexofenadine	221-233	ATP binding cassette subfamily B member 1	Homo sapiens	53-57
14610227-5	2004	Dehydroepiandrosterone-sulfate, estrone-3-sulfate, and fexofenadine were transported by OATP-B at both neutral and acidic pH, whereas estradiol-17beta-glucuronide, acetic acid, and lactic acid were not transported at all.	fexofenadine	55-67	solute carrier organic anion transporter family member 2B1	Homo sapiens	88-94
15460210-1	2004	The influence of fexofenadine hydrochloride (FEX; CAS 138452-21-8) on the production of eosinophil chemoattractants, RANTES and eotaxin, from nasal polyp fibroblasts (NPFs) was examined in vitro.	fexofenadine	45-48	C-C motif chemokine ligand 5	Homo sapiens	117-123
14530792-7	2003	In addition, fexofenadine has proven anti-inflammatory activity and has been shown to inhibit a number of mediators at clinically relevant concentrations, including in vitro inhibition of ICAM-1 expression on conjunctival and nasal epithelial cells.	fexofenadine	13-25	intercellular adhesion molecule 1	Homo sapiens	188-194
14586383-11	2003	However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.	fexofenadine	156-168	MAX-like protein X	Mus musculus	266-270
14586383-11	2003	However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.	fexofenadine	156-168	MAX-like protein X	Mus musculus	293-297
14586383-14	2003	The most plausible mechanism is either decreased organic anion transporting polypeptide-mediated sinusoidal uptake or P-glycoprotein-mediated canalicular secretion of fexofenadine, or both.	fexofenadine	167-179	ATP binding cassette subfamily B member 1	Homo sapiens	118-132
12575922-11	2002	After treatment with fexofenadine, there was a significant decrease in the expression of ELAM-1 (p= 0.02), VCAM-1 (p= 0.04) and tryptase (p= 0.04), whereas no relevant change was observed for the other parameters examined.	fexofenadine	21-33	selectin E	Homo sapiens	89-95
12411421-5	2002	In the present study the ability of fexofenadine to block the K897T HERG channel variant was investigated.	fexofenadine	36-48	potassium voltage-gated channel subfamily H member 2	Homo sapiens	68-72
12575922-11	2002	After treatment with fexofenadine, there was a significant decrease in the expression of ELAM-1 (p= 0.02), VCAM-1 (p= 0.04) and tryptase (p= 0.04), whereas no relevant change was observed for the other parameters examined.	fexofenadine	21-33	vascular cell adhesion molecule 1	Homo sapiens	107-113
11703220-5	2001	RESULTS: The total symptom score was reduced by fexofenadine (both dosages) at V2 (P=0.007), whereas placebo did not modify it.	fexofenadine	48-60	nibrin	Homo sapiens	76-81
12070109-5	2002	We tested terfenadine carboxylate (fexofenadine) and terfenadine, structurally similar drugs with markedly different affinities for HERG block, for rescue of trafficking-defective LQT2 mutations.	fexofenadine	10-33	potassium voltage-gated channel subfamily H member 2	Homo sapiens	180-184
11994059-0	2002	MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.	fexofenadine	72-84	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
11994059-0	2002	MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.	fexofenadine	72-84	ATP binding cassette subfamily B member 1	Homo sapiens	47-61
11823753-0	2002	Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.	fexofenadine	118-130	solute carrier organic anion transporter family member 1A2	Homo sapiens	21-59
11823753-3	2002	OATP-mediated fexofenadine uptake was measured in a transfected cell line.	fexofenadine	14-26	solute carrier organic anion transporter family member 1A2	Homo sapiens	0-4
12087344-4	2002	Fexofenadine, 60 mg, was administered orally before administration of St John"s wort, with a single dose of St John"s wort (900 mg), and after 2 weeks of treatment with St John"s wort (300 mg 3 times a day) to determine P-glycoprotein activity.	fexofenadine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	220-234
12134950-3	2002	Rhodamine123, fexofenadine and saquinavir were used as P-gp substrates.	fexofenadine	14-26	phosphoglycolate phosphatase	Rattus norvegicus	55-59
11503014-7	2001	In humans, MDR1*1 and MDR1*2 variants were associated with differences in fexofenadine levels, consistent with the in vitro data, with the area under the plasma level-time curve being almost 40% greater in the *1/*1 genotype compared with the *2/*2 and the *1/*2 heterozygotes having an intermediate value, suggesting enhanced in vivo P-glycoprotein activity among subjects with the MDR1*2 allele.	fexofenadine	74-86	ATP binding cassette subfamily B member 1	Homo sapiens	11-15
11503014-7	2001	In humans, MDR1*1 and MDR1*2 variants were associated with differences in fexofenadine levels, consistent with the in vitro data, with the area under the plasma level-time curve being almost 40% greater in the *1/*1 genotype compared with the *2/*2 and the *1/*2 heterozygotes having an intermediate value, suggesting enhanced in vivo P-glycoprotein activity among subjects with the MDR1*2 allele.	fexofenadine	74-86	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
11503014-7	2001	In humans, MDR1*1 and MDR1*2 variants were associated with differences in fexofenadine levels, consistent with the in vitro data, with the area under the plasma level-time curve being almost 40% greater in the *1/*1 genotype compared with the *2/*2 and the *1/*2 heterozygotes having an intermediate value, suggesting enhanced in vivo P-glycoprotein activity among subjects with the MDR1*2 allele.	fexofenadine	74-86	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
11238657-6	2001	Histamine-induced beta-glucuronidase and IL-6 release and [Ca(2+)](i) elevation were inhibited by the selective H(1) antagonist fexofenadine (10(-7)-10(-4) M), but not by the H(2) antagonist ranitidine.	fexofenadine	128-140	interleukin 6	Homo sapiens	41-45
11238657-6	2001	Histamine-induced beta-glucuronidase and IL-6 release and [Ca(2+)](i) elevation were inhibited by the selective H(1) antagonist fexofenadine (10(-7)-10(-4) M), but not by the H(2) antagonist ranitidine.	fexofenadine	128-140	glucuronidase beta	Homo sapiens	18-36
11257421-6	2001	In P-gp-deficient mice, DPDPE uptake was saturable (K(m) approximately 24 mM), and was inhibited by dexverapamil and the Oatp2 substrates digoxin, estradiol-17beta-glucuronide and fexofenadine.	fexofenadine	180-192	solute carrier organic anion transporter family, member 1a4	Mus musculus	121-126
11238657-7	2001	Inhibition of histamine-induced beta-glucuronidase and IL-6 release by fexofenadine was concentration dependent and displayed the characteristics of a competitive antagonism (K(d) = 89 nM).	fexofenadine	71-83	glucuronidase beta	Homo sapiens	32-50
11238657-7	2001	Inhibition of histamine-induced beta-glucuronidase and IL-6 release by fexofenadine was concentration dependent and displayed the characteristics of a competitive antagonism (K(d) = 89 nM).	fexofenadine	71-83	interleukin 6	Homo sapiens	55-59
11240975-7	2001	The amount of azacyclonol, a CYP3A4 mediated metabolite of fexofenadine, eliminated renally increased on average 2-fold after rifampin dosing; however, this pathway accounted for less than 0.5% of the dose.	fexofenadine	59-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-35
10444235-6	1999	In fact, other molecules such as cetirizine, loratadine, acrivastine, and fexofenadine seem to lack both cardiotoxic potential and HERG-blocking ability at therapeutically relevant concentrations.	fexofenadine	74-86	potassium voltage-gated channel subfamily H member 2	Homo sapiens	131-135
10730552-1	2000	UNLABELLED: Fexofenadine, the active metabolite of terfenadine, is a selective histamine H1 receptor antagonist that does not cross the blood brain barrier and appears to display some anti-inflammatory properties.	fexofenadine	12-24	histamine receptor H1	Homo sapiens	79-100
10421612-0	1999	OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.	fexofenadine	82-94	solute carrier organic anion transporter family member 1A2	Homo sapiens	0-4
10421612-0	1999	OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.	fexofenadine	82-94	ATP binding cassette subfamily B member 1	Homo sapiens	9-23
10421612-3	1999	Utilizing a recombinant vaccinia expression system, members of the organic anion transporting polypeptide family, such as the human organic anion transporting polypeptide (OATP) and rat organic anion transporting polypeptides 1 and 2 (Oatp1 and Oatp2), were found to mediate [(14)C]fexofenadine cellular uptake.	fexofenadine	282-294	solute carrier organic anion transporter family member 1A2	Homo sapiens	67-105
10421612-7	1999	administration of [(14)C]fexofenadine to mice lacking mdr1a-encoded P-gp resulted in 5- and 9-fold increases in the drug"s plasma and brain levels, respectively, compared with wild-type mice.	fexofenadine	25-37	phosphoglycolate phosphatase	Mus musculus	68-72
10421612-9	1999	Because OATP transporters and P-gp colocalize in organs of importance to drug disposition such as the liver, their activity provides an explanation for the heretofore unknown mechanism(s) responsible for fexofenadine"s disposition and suggests potentially similar roles in the disposition of other xenobiotics.	fexofenadine	204-216	solute carrier organic anion transporter family member 1A2	Homo sapiens	8-12
10421612-9	1999	Because OATP transporters and P-gp colocalize in organs of importance to drug disposition such as the liver, their activity provides an explanation for the heretofore unknown mechanism(s) responsible for fexofenadine"s disposition and suggests potentially similar roles in the disposition of other xenobiotics.	fexofenadine	204-216	ATP binding cassette subfamily B member 1	Homo sapiens	30-34
10496299-12	1999	Troglitazone may enhance the activities of cytochrome P450 (CYP) 3A and/or transporter(s) thereby reducing the plasma concentrations of terfenadine, cyclosporin, atorvastatin and fexofenadine.	fexofenadine	179-191	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-67
10384858-7	1999	Fexofenadine, eliminated largely unchanged in the faeces and urine, has a terminal t1/2 beta of approximately 14 hours and duration of action of 24 hours, making it suitable for once or twice daily administration.	fexofenadine	0-12	interleukin 1 receptor like 1	Homo sapiens	83-92
9892033-0	1998	Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines.	fexofenadine	16-28	intercellular adhesion molecule 1	Homo sapiens	45-51
9892033-3	1998	OBJECTIVE: The aim of the study was to evaluate the effect exerted by terfenadine and fexofenadine on adhesion molecules expression (CD54/ICAM-1 and CD29) of a human continuously cultured conjunctival epithelial cell line (WK) and a fibroblast cell line (HEL).	fexofenadine	86-98	intercellular adhesion molecule 1	Homo sapiens	133-137
9892033-6	1998	RESULTS: Terfenadine and fexofenadine significantly reduced ICAM-1 basal expression on WK cells at the concentration of 1 microg/mL and 50 microg/mL, respectively.	fexofenadine	25-37	intercellular adhesion molecule 1	Homo sapiens	60-66
9892033-7	1998	In addition, both terfenadine and fexofenadine were able to decrease soluble ICAM-1 levels in IFN gamma-stimulated WK cells.	fexofenadine	34-46	intercellular adhesion molecule 1	Homo sapiens	77-83
9892033-7	1998	In addition, both terfenadine and fexofenadine were able to decrease soluble ICAM-1 levels in IFN gamma-stimulated WK cells.	fexofenadine	34-46	interferon gamma	Homo sapiens	94-103
9892033-8	1998	On HEL fibroblasts, fexofenadine only was able to inhibit ICAM-1 upregulation induced by IFN gamma.	fexofenadine	20-32	intercellular adhesion molecule 1	Homo sapiens	58-64
9892033-8	1998	On HEL fibroblasts, fexofenadine only was able to inhibit ICAM-1 upregulation induced by IFN gamma.	fexofenadine	20-32	interferon gamma	Homo sapiens	89-98
9892033-9	1998	Concerning the release of fibroblast products, we observed a dose-dependent decrease of spontaneous IL6 release only in the presence of fexofenadine.	fexofenadine	136-148	interleukin 6	Homo sapiens	100-103
9892033-10	1998	CONCLUSION: This study shows that terfenadine and fexofenadine exert a biologic effect directly on epithelial cells and fibroblasts reducing ICAM-1 expression and partially reducing soluble ICAM-1 release.	fexofenadine	50-62	intercellular adhesion molecule 1	Homo sapiens	141-147
9892033-10	1998	CONCLUSION: This study shows that terfenadine and fexofenadine exert a biologic effect directly on epithelial cells and fibroblasts reducing ICAM-1 expression and partially reducing soluble ICAM-1 release.	fexofenadine	50-62	intercellular adhesion molecule 1	Homo sapiens	190-196
9506246-1	1998	The nonsedating histamine H1 receptor antagonist fexofenadine is the active metabolite of terfenadine.	fexofenadine	49-61	histamine receptor H1	Homo sapiens	16-37
9525460-7	1998	The eosinophil-induced release of IL-8, GM-CSF, and sICAM-1 from the HNEC was significantly attenuated by treatment with fexofenadine.	fexofenadine	121-133	C-X-C motif chemokine ligand 8	Homo sapiens	34-38
9525460-7	1998	The eosinophil-induced release of IL-8, GM-CSF, and sICAM-1 from the HNEC was significantly attenuated by treatment with fexofenadine.	fexofenadine	121-133	colony stimulating factor 2	Homo sapiens	40-46
33825113-1	2021	PURPOSE: Fexofenadine is a well-identified in vivo probe substrate of P-glycoprotein (P-gp) and/or organic anion transporting polypeptide (OATP).	fexofenadine	9-21	ATP binding cassette subfamily B member 1	Homo sapiens	70-84
33825113-1	2021	PURPOSE: Fexofenadine is a well-identified in vivo probe substrate of P-glycoprotein (P-gp) and/or organic anion transporting polypeptide (OATP).	fexofenadine	9-21	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
33825113-1	2021	PURPOSE: Fexofenadine is a well-identified in vivo probe substrate of P-glycoprotein (P-gp) and/or organic anion transporting polypeptide (OATP).	fexofenadine	9-21	solute carrier organic anion transporter family member 1A2	Homo sapiens	99-137
33825113-1	2021	PURPOSE: Fexofenadine is a well-identified in vivo probe substrate of P-glycoprotein (P-gp) and/or organic anion transporting polypeptide (OATP).	fexofenadine	9-21	solute carrier organic anion transporter family member 1A2	Homo sapiens	139-143
33825113-2	2021	This work aimed to investigate the transplacental pharmacokinetics of fexofenadine enantiomers with and without the selective P-gp inhibitor fluoxetine.	fexofenadine	70-82	ATP binding cassette subfamily B member 1	Homo sapiens	126-130
33825113-10	2021	CONCLUSIONS: Our study showed a low extent, slow rate of non-enantioselective placental transfer of fexofenadine enantiomers, indicating a limited fetal fexofenadine exposure mediated by placental P-gp and/or OATP2B1.	fexofenadine	100-112	solute carrier organic anion transporter family member 2B1	Homo sapiens	209-216
28712300-14	2017	As proof of concept, incorporating OATP2B1 and P-gp markedly improved the EOC and predicted Cmax and Tmax for fexofenadine.	fexofenadine	110-122	solute carrier organic anion transporter family member 2B1	Homo sapiens	35-42
28712300-14	2017	As proof of concept, incorporating OATP2B1 and P-gp markedly improved the EOC and predicted Cmax and Tmax for fexofenadine.	fexofenadine	110-122	phosphoglycolate phosphatase	Homo sapiens	47-51
35403732-6	2022	Administration of fexofenadine, a histamine H1 receptor antagonist, suppressed tumor growth in HFD-fed mice by reducing the number of myeloid-derived suppressor cells and suppressing IL6/STAT3 signaling.	fexofenadine	18-30	histamine receptor H1	Mus musculus	34-55
34917820-3	2021	This study aimed to evaluate the effect of fexofenadine and fluticasone propionate on the gene expression levels of Interferon regulatory factor 4 (IRF4), B cell-activating transcription factor-like (BATF), and SPI1 gene-encoded protein (PU.1), essential transcription factors for Th9 cell differentiation, in AR patients.	fexofenadine	43-55	interferon regulatory factor 4	Homo sapiens	116-146
34917820-3	2021	This study aimed to evaluate the effect of fexofenadine and fluticasone propionate on the gene expression levels of Interferon regulatory factor 4 (IRF4), B cell-activating transcription factor-like (BATF), and SPI1 gene-encoded protein (PU.1), essential transcription factors for Th9 cell differentiation, in AR patients.	fexofenadine	43-55	interferon regulatory factor 4	Homo sapiens	148-152
34917820-3	2021	This study aimed to evaluate the effect of fexofenadine and fluticasone propionate on the gene expression levels of Interferon regulatory factor 4 (IRF4), B cell-activating transcription factor-like (BATF), and SPI1 gene-encoded protein (PU.1), essential transcription factors for Th9 cell differentiation, in AR patients.	fexofenadine	43-55	basic leucine zipper ATF-like transcription factor	Homo sapiens	155-198
34917820-3	2021	This study aimed to evaluate the effect of fexofenadine and fluticasone propionate on the gene expression levels of Interferon regulatory factor 4 (IRF4), B cell-activating transcription factor-like (BATF), and SPI1 gene-encoded protein (PU.1), essential transcription factors for Th9 cell differentiation, in AR patients.	fexofenadine	43-55	basic leucine zipper ATF-like transcription factor	Homo sapiens	200-204
34917820-3	2021	This study aimed to evaluate the effect of fexofenadine and fluticasone propionate on the gene expression levels of Interferon regulatory factor 4 (IRF4), B cell-activating transcription factor-like (BATF), and SPI1 gene-encoded protein (PU.1), essential transcription factors for Th9 cell differentiation, in AR patients.	fexofenadine	43-55	Spi-1 proto-oncogene	Homo sapiens	211-215
34917820-3	2021	This study aimed to evaluate the effect of fexofenadine and fluticasone propionate on the gene expression levels of Interferon regulatory factor 4 (IRF4), B cell-activating transcription factor-like (BATF), and SPI1 gene-encoded protein (PU.1), essential transcription factors for Th9 cell differentiation, in AR patients.	fexofenadine	43-55	Spi-1 proto-oncogene	Homo sapiens	238-242
34917820-7	2021	Overall, our results showed that after one month of treatment with fexofenadine and fluticasone propionate, the expression levels of IRF4 and BATF genes in AR patients decreased, which may be due to this treatment regimen.	fexofenadine	67-79	interferon regulatory factor 4	Homo sapiens	133-137
34917820-7	2021	Overall, our results showed that after one month of treatment with fexofenadine and fluticasone propionate, the expression levels of IRF4 and BATF genes in AR patients decreased, which may be due to this treatment regimen.	fexofenadine	67-79	basic leucine zipper ATF-like transcription factor	Homo sapiens	142-146
34504840-0	2021	Fexofenadine Protects Against Intervertebral Disc Degeneration Through TNF Signaling.	fexofenadine	0-12	tumor necrosis factor	Rattus norvegicus	71-74
34826148-0	2022	Addition of oral Fexofenadine to topical therapy leads to a significantly greater reduction in the serum IL-31 levels in mild to moderate pediatric atopic dermatitis.	fexofenadine	17-29	interleukin 31	Homo sapiens	105-110
34826148-6	2022	However, the serum IL-31 (ng/ml) decreased significantly from baseline in the fexofenadine group after 8 weeks of treatment.	fexofenadine	78-90	interleukin 31	Homo sapiens	19-24
34826148-7	2022	CONCLUSIONS: Although we could not conclusively confirm the clinical efficacy of adding oral fexofenadine to topical treatment in AD, serological evaluation indicates that fexofenadine treatment can lead to significant lowering of serum IL-31 levels in AD patients.	fexofenadine	93-105	interleukin 31	Homo sapiens	237-242
34826148-7	2022	CONCLUSIONS: Although we could not conclusively confirm the clinical efficacy of adding oral fexofenadine to topical treatment in AD, serological evaluation indicates that fexofenadine treatment can lead to significant lowering of serum IL-31 levels in AD patients.	fexofenadine	172-184	interleukin 31	Homo sapiens	237-242
34681815-0	2021	Cytosolic Phospholipase A2 Is Required for Fexofenadine"s Therapeutic Effects against Inflammatory Bowel Disease in Mice.	fexofenadine	43-55	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	0-26
34681815-3	2021	We recently identified fexofenadine, a well-known antagonist of histamine H1 receptor, as a novel inhibitor of TNFalpha signaling.	fexofenadine	23-35	histamine receptor H1	Mus musculus	64-85
34681815-3	2021	We recently identified fexofenadine, a well-known antagonist of histamine H1 receptor, as a novel inhibitor of TNFalpha signaling.	fexofenadine	23-35	tumor necrosis factor	Mus musculus	111-119
34681815-4	2021	Additionally, cytosolic phospholipase A2 (cPLA2) was isolated as a binding target of fexofenadine, and fexofenadine-mediated anti-TNF activity relied on cPLA2 in vitro.	fexofenadine	85-97	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	14-40
34681815-4	2021	Additionally, cytosolic phospholipase A2 (cPLA2) was isolated as a binding target of fexofenadine, and fexofenadine-mediated anti-TNF activity relied on cPLA2 in vitro.	fexofenadine	85-97	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	42-47
34681815-4	2021	Additionally, cytosolic phospholipase A2 (cPLA2) was isolated as a binding target of fexofenadine, and fexofenadine-mediated anti-TNF activity relied on cPLA2 in vitro.	fexofenadine	103-115	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	14-40
34681815-4	2021	Additionally, cytosolic phospholipase A2 (cPLA2) was isolated as a binding target of fexofenadine, and fexofenadine-mediated anti-TNF activity relied on cPLA2 in vitro.	fexofenadine	103-115	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	42-47
34681815-4	2021	Additionally, cytosolic phospholipase A2 (cPLA2) was isolated as a binding target of fexofenadine, and fexofenadine-mediated anti-TNF activity relied on cPLA2 in vitro.	fexofenadine	103-115	tumor necrosis factor	Mus musculus	130-133
34681815-4	2021	Additionally, cytosolic phospholipase A2 (cPLA2) was isolated as a binding target of fexofenadine, and fexofenadine-mediated anti-TNF activity relied on cPLA2 in vitro.	fexofenadine	103-115	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	153-158
34681815-5	2021	The objective of this study is to determine whether fexofenadine is therapeutic against chemically-induced murine IBD model and whether cPLA2 and/or histamine H1 receptor is important for fexofenadine"s anti-inflammatory activity in vivo by leveraging various genetically modified mice and chemically induced murine IBD models.	fexofenadine	188-200	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	136-141
34681815-5	2021	The objective of this study is to determine whether fexofenadine is therapeutic against chemically-induced murine IBD model and whether cPLA2 and/or histamine H1 receptor is important for fexofenadine"s anti-inflammatory activity in vivo by leveraging various genetically modified mice and chemically induced murine IBD models.	fexofenadine	188-200	histamine receptor H1	Mus musculus	149-170
34681815-6	2021	Both dextran sulfate sodium- and 2, 4, 6-trinitrobenzene sulfonic acid-induced murine IBD models revealed that orally delivered fexofenadine was therapeutic against IBD, evidenced by mitigated clinical symptoms, decreased secretions of the proinflammatory cytokine IL-6 and IL-1beta, lowered intestinal inflammation, and reduced p-p65 and p-IkBalpha.	fexofenadine	128-140	interleukin 6	Mus musculus	265-269
34681815-6	2021	Both dextran sulfate sodium- and 2, 4, 6-trinitrobenzene sulfonic acid-induced murine IBD models revealed that orally delivered fexofenadine was therapeutic against IBD, evidenced by mitigated clinical symptoms, decreased secretions of the proinflammatory cytokine IL-6 and IL-1beta, lowered intestinal inflammation, and reduced p-p65 and p-IkBalpha.	fexofenadine	128-140	interleukin 1 alpha	Mus musculus	274-282
34681815-6	2021	Both dextran sulfate sodium- and 2, 4, 6-trinitrobenzene sulfonic acid-induced murine IBD models revealed that orally delivered fexofenadine was therapeutic against IBD, evidenced by mitigated clinical symptoms, decreased secretions of the proinflammatory cytokine IL-6 and IL-1beta, lowered intestinal inflammation, and reduced p-p65 and p-IkBalpha.	fexofenadine	128-140	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	331-334
34681815-7	2021	Intriguingly, Fexofenadine-mediated protective effects against IBD were lost in cPLA2 deficient mice but not in histamine H1 receptor-deficient mice.	fexofenadine	14-26	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	80-85
34681815-8	2021	Collectively, these findings demonstrate the therapeutic effects of over-the-counter drug Fexofenadine in treating DSS-induced IBD murine and provide first in vivo evidence showing that cPLA2 is required for fexofenadine"s therapeutic effects in murine IBD model and probably other inflammatory and autoimmune diseases as well.	fexofenadine	208-220	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	186-191
35403732-6	2022	Administration of fexofenadine, a histamine H1 receptor antagonist, suppressed tumor growth in HFD-fed mice by reducing the number of myeloid-derived suppressor cells and suppressing IL6/STAT3 signaling.	fexofenadine	18-30	interleukin 6	Mus musculus	183-186
35403732-6	2022	Administration of fexofenadine, a histamine H1 receptor antagonist, suppressed tumor growth in HFD-fed mice by reducing the number of myeloid-derived suppressor cells and suppressing IL6/STAT3 signaling.	fexofenadine	18-30	signal transducer and activator of transcription 3	Mus musculus	187-192
33372901-2	2020	Pgp activity was analyzed in a transwell system by the transport of its substrate, fexofenadine.	fexofenadine	83-95	ATP binding cassette subfamily B member 1	Homo sapiens	0-3
35455642-7	2022	CYP3A and P-gp phenotypic activities were assessed by the metabolic ratio of midazolam and AUC0-6h of fexofenadine, respectively.	fexofenadine	102-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
35455642-7	2022	CYP3A and P-gp phenotypic activities were assessed by the metabolic ratio of midazolam and AUC0-6h of fexofenadine, respectively.	fexofenadine	102-114	phosphoglycolate phosphatase	Homo sapiens	10-14
33256506-0	2021	Effects of Breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.	fexofenadine	85-97	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
33256506-0	2021	Effects of Breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.	fexofenadine	85-97	ATP binding cassette subfamily B member 1	Homo sapiens	101-115
33256506-4	2021	The aim of this study was to evaluate the effect of BRE on the pharmacokinetics of fexofenadine, a P-gp probe substrate and its associations with the MDR1 C3435T genetic polymorphism in healthy volunteers.	fexofenadine	83-95	ATP binding cassette subfamily B member 1	Homo sapiens	99-103
33256506-4	2021	The aim of this study was to evaluate the effect of BRE on the pharmacokinetics of fexofenadine, a P-gp probe substrate and its associations with the MDR1 C3435T genetic polymorphism in healthy volunteers.	fexofenadine	83-95	ATP binding cassette subfamily B member 1	Homo sapiens	150-154
33832418-5	2021	The transport of the P-gp substrate fexofenadine was evaluated in a special Transwell system.	fexofenadine	36-48	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
35230114-3	2022	Inhibitory potency was assessed by examining the uptake of (3H)estrone 3-sulfate and (3H)fexofenadine into HEK293 cells expressing OATP1A2 or OATP2B1.	fexofenadine	89-101	solute carrier organic anion transporter family member 1A2	Homo sapiens	131-138
32571913-6	2020	40, a common azo dye excipient and a potent inhibitor of OATP2B1, decreased the plasma level of the OATP2B1 substrate fexofenadine, suggesting that FD&C Red No.	fexofenadine	118-130	solute carrier organic anion transporter family member 2B1	Homo sapiens	57-64
32571913-6	2020	40, a common azo dye excipient and a potent inhibitor of OATP2B1, decreased the plasma level of the OATP2B1 substrate fexofenadine, suggesting that FD&C Red No.	fexofenadine	118-130	solute carrier organic anion transporter family member 2B1	Homo sapiens	100-107
32557079-2	2020	Fexofenadine, an in vivo P-gp probe, is an antihistamine drug for seasonal allergic rhinitis and chronic urticaria treatment during pregnancy and it is available as a racemic mixture.	fexofenadine	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	25-29
32557079-10	2020	CONCLUSIONS: A single oral dose of 40 mg fluoxetine inhibited the intestinal P-gp mediated transport of S-(-)-fexofenadine to a greater extent than R-(+)-fexofenadine in parturient women.	fexofenadine	104-122	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
30652318-5	2019	In contrast, atorvastatin, bosentan, etoposide, fexofenadine, fluvastatin, glibenclamide and simeprevir were broadly transported by recombinant monkey OATP1B1, OATP1B3 and OATP2B1.	fexofenadine	48-60	solute carrier organic anion transporter family member 1B1	Homo sapiens	151-158
32078103-8	2020	The absorption of oral verapamil, diltiazem and tacrolimus was not influenced by elacridar pre-treatment, and the increase in the AUC0-t of fexofenadine was approximately 3-fold when co-administered with each substrate; the minimal effect of elacridar was attributable to the limited contribution of P-gp but not to their self-inhibition against the transporter.	fexofenadine	140-152	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	300-304
32115554-3	2020	In the present study, we designed a prodrug of fexofenadine (FXD) as a model parent drug that is resistant to hCE2 but hydrolyzed by hCE1, utilizing the differences in catalytic characteristics of hCE1 and hCE2.	fexofenadine	47-59	carboxylesterase 2	Homo sapiens	110-114
32115554-3	2020	In the present study, we designed a prodrug of fexofenadine (FXD) as a model parent drug that is resistant to hCE2 but hydrolyzed by hCE1, utilizing the differences in catalytic characteristics of hCE1 and hCE2.	fexofenadine	47-59	carboxylesterase 1	Homo sapiens	133-137
32115554-3	2020	In the present study, we designed a prodrug of fexofenadine (FXD) as a model parent drug that is resistant to hCE2 but hydrolyzed by hCE1, utilizing the differences in catalytic characteristics of hCE1 and hCE2.	fexofenadine	47-59	carboxylesterase 1	Homo sapiens	197-201
32115554-3	2020	In the present study, we designed a prodrug of fexofenadine (FXD) as a model parent drug that is resistant to hCE2 but hydrolyzed by hCE1, utilizing the differences in catalytic characteristics of hCE1 and hCE2.	fexofenadine	47-59	carboxylesterase 2	Homo sapiens	206-210
31581637-4	2019	As part of a study evaluating potential drug-drug interactions between probe drugs of the Geneva cocktail, the present paper focuses on the impact of cytochromes (CYP) probe drugs on the disposition of fexofenadine, a P-gp test drug.	fexofenadine	202-214	peptidylprolyl isomerase G	Homo sapiens	163-166
31581637-4	2019	As part of a study evaluating potential drug-drug interactions between probe drugs of the Geneva cocktail, the present paper focuses on the impact of cytochromes (CYP) probe drugs on the disposition of fexofenadine, a P-gp test drug.	fexofenadine	202-214	ATP binding cassette subfamily B member 1	Homo sapiens	218-222
31183371-8	2019	Conclusions: Our study revealed for the first time that second-generation antihistamines, including cetirizine, fexofenadine, azelastine, and terfenadine, exert suppressive effects on lymphocyte Kv1.3-channels.	fexofenadine	112-124	potassium voltage-gated channel, shaker-related subfamily, member 3	Mus musculus	195-200
31317804-3	2020	Buspirone and fexofenadine, probe substrates of CYP3A and P-glycoprotein (P-gp), respectively, were orally co-administered to rats with bergamottin (2.5 mg/kg) or orally administered 2 h after bergamottin pre-treatment.	fexofenadine	14-26	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	48-53
31317804-3	2020	Buspirone and fexofenadine, probe substrates of CYP3A and P-glycoprotein (P-gp), respectively, were orally co-administered to rats with bergamottin (2.5 mg/kg) or orally administered 2 h after bergamottin pre-treatment.	fexofenadine	14-26	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	58-72
31317804-3	2020	Buspirone and fexofenadine, probe substrates of CYP3A and P-glycoprotein (P-gp), respectively, were orally co-administered to rats with bergamottin (2.5 mg/kg) or orally administered 2 h after bergamottin pre-treatment.	fexofenadine	14-26	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	74-78
31746415-12	2020	In 293-OATP1A2 cells, the uptake of FEX without OATP1A2 inhibitor naringenin (100 microg/ml) was 2.8-fold higher compared with that in the presence of naringenin, and the uptake of fentanyl without naringenin was 7.3-fold higher compared with that in the presence of naringenin (100 microg/ml).	fexofenadine	36-39	solute carrier organic anion transporter family member 1A2	Homo sapiens	7-14
31302596-0	2019	Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis.	fexofenadine	0-12	tumor necrosis factor	Mus musculus	22-25
31302596-0	2019	Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis.	fexofenadine	0-12	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	57-83
31302596-3	2019	METHODS: In vitro and in vivo screening of an Food and Drug Administration (FDA)-approved drug library; in vitro and in vivo assays for examining the blockade of TNF actions by fexofenadine: assays for defining the anti-inflammatory activity of fexofenadine using TNF-alpha transgenic (TNF-tg) mice and collagen-induced arthritis in DBA/1 mice.	fexofenadine	177-189	tumor necrosis factor	Mus musculus	162-165
31302596-4	2019	Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine"s anti-TNF activity on cPLA2.	fexofenadine	54-66	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	70-96
31302596-4	2019	Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine"s anti-TNF activity on cPLA2.	fexofenadine	54-66	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	98-103
31302596-4	2019	Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine"s anti-TNF activity on cPLA2.	fexofenadine	54-66	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	309-314
31302596-4	2019	Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine"s anti-TNF activity on cPLA2.	fexofenadine	54-66	tumor necrosis factor	Mus musculus	364-367
31302596-4	2019	Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine"s anti-TNF activity on cPLA2.	fexofenadine	54-66	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	309-314
31302596-4	2019	Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine"s anti-TNF activity on cPLA2.	fexofenadine	282-294	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	70-96
31302596-4	2019	Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine"s anti-TNF activity on cPLA2.	fexofenadine	282-294	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	98-103
31302596-4	2019	Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine"s anti-TNF activity on cPLA2.	fexofenadine	282-294	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	70-96
31302596-4	2019	Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine"s anti-TNF activity on cPLA2.	fexofenadine	282-294	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	98-103
31302596-5	2019	RESULTS: Serial screenings of a library composed of FDA-approved drugs led to the identification of fexofenadine as an inhibitor of TNF-alpha signalling.	fexofenadine	100-112	tumor necrosis factor	Mus musculus	132-141
31302596-7	2019	cPLA2 was isolated as a novel target of fexofenadine.	fexofenadine	40-52	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	0-5
31302596-8	2019	Fexofenadine blocked TNF-stimulated cPLA2 activity and arachidonic acid production through binding to catalytic domain 2 of cPLA2 and inhibition of its phosphorylation on Ser-505.	fexofenadine	0-12	tumor necrosis factor	Mus musculus	21-24
31302596-8	2019	Fexofenadine blocked TNF-stimulated cPLA2 activity and arachidonic acid production through binding to catalytic domain 2 of cPLA2 and inhibition of its phosphorylation on Ser-505.	fexofenadine	0-12	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	36-41
31302596-8	2019	Fexofenadine blocked TNF-stimulated cPLA2 activity and arachidonic acid production through binding to catalytic domain 2 of cPLA2 and inhibition of its phosphorylation on Ser-505.	fexofenadine	0-12	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	124-129
31302596-9	2019	Further, deletion of cPLA2 abolished fexofenadine"s anti-TNF activity.	fexofenadine	37-49	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	21-26
31302596-9	2019	Further, deletion of cPLA2 abolished fexofenadine"s anti-TNF activity.	fexofenadine	37-49	tumor necrosis factor	Mus musculus	57-60
31302596-10	2019	CONCLUSION: Collectively, these findings not only provide new insights into the understanding of fexofenadine action and underlying mechanisms but also provide new therapeutic interventions for various TNF-alpha and cPLA2-associated pathologies and conditions, particularly inflammatory rheumatic diseases.	fexofenadine	97-109	tumor necrosis factor	Mus musculus	202-211
31302596-10	2019	CONCLUSION: Collectively, these findings not only provide new insights into the understanding of fexofenadine action and underlying mechanisms but also provide new therapeutic interventions for various TNF-alpha and cPLA2-associated pathologies and conditions, particularly inflammatory rheumatic diseases.	fexofenadine	97-109	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	216-221
30875094-0	2019	Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.	fexofenadine	14-26	epidermal growth factor receptor	Homo sapiens	85-89
30953868-10	2019	CONCLUSIONS: This study shows that fexofenadine (FXF - antihistamine drug) and osthole exhibit selective COX-2 enzyme inhibitory activity.	fexofenadine	35-47	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	105-110
30652318-5	2019	In contrast, atorvastatin, bosentan, etoposide, fexofenadine, fluvastatin, glibenclamide and simeprevir were broadly transported by recombinant monkey OATP1B1, OATP1B3 and OATP2B1.	fexofenadine	48-60	solute carrier organic anion transporter family member 1B3	Homo sapiens	160-167
30652318-5	2019	In contrast, atorvastatin, bosentan, etoposide, fexofenadine, fluvastatin, glibenclamide and simeprevir were broadly transported by recombinant monkey OATP1B1, OATP1B3 and OATP2B1.	fexofenadine	48-60	solute carrier organic anion transporter family member 2B1	Homo sapiens	172-179
30280663-2	2019	This guidance has indicated that digoxin, dabigatran etexilate and fexofenadine are P-gp substrate drugs and has defined P-gp inhibitors as those that increase the AUC of digoxin by  1.25-fold in clinical DDI studies.	fexofenadine	67-79	ATP binding cassette subfamily B member 1	Homo sapiens	84-88
30280663-2	2019	This guidance has indicated that digoxin, dabigatran etexilate and fexofenadine are P-gp substrate drugs and has defined P-gp inhibitors as those that increase the AUC of digoxin by  1.25-fold in clinical DDI studies.	fexofenadine	67-79	ATP binding cassette subfamily B member 1	Homo sapiens	121-125
30742585-0	2019	Effect of the Fexofenadine on the expression of HRH-1 and HRH-4 receptor in Peripheral Blood Mononuclear Cell isolated from children with diagnosed allergy - in vitro study Short communication.	fexofenadine	14-26	histamine receptor H1	Homo sapiens	48-53
30280663-4	2019	OBJECTIVE: Since there are no detailed manuscripts that summarizes P-gp interactions unrelated to CYP metabolism, this article reviews the effects of potent P-gp inhibitors and P-gp inducers on the pharmacokinetics of P-gp substrate drugs, including digoxin, talinolol, dabigatran etexilate, and fexofenadine in human studies.	fexofenadine	296-308	ATP binding cassette subfamily B member 1	Homo sapiens	157-161
30280663-4	2019	OBJECTIVE: Since there are no detailed manuscripts that summarizes P-gp interactions unrelated to CYP metabolism, this article reviews the effects of potent P-gp inhibitors and P-gp inducers on the pharmacokinetics of P-gp substrate drugs, including digoxin, talinolol, dabigatran etexilate, and fexofenadine in human studies.	fexofenadine	296-308	ATP binding cassette subfamily B member 1	Homo sapiens	157-161
30280663-4	2019	OBJECTIVE: Since there are no detailed manuscripts that summarizes P-gp interactions unrelated to CYP metabolism, this article reviews the effects of potent P-gp inhibitors and P-gp inducers on the pharmacokinetics of P-gp substrate drugs, including digoxin, talinolol, dabigatran etexilate, and fexofenadine in human studies.	fexofenadine	296-308	ATP binding cassette subfamily B member 1	Homo sapiens	157-161
27864798-8	2017	One study using a midazolam probe found weak CYP3A induction and another using a fexofenadine probe found weak P-gp inhibition.	fexofenadine	81-93	phosphoglycolate phosphatase	Homo sapiens	111-115
30020547-1	2018	Thirty-two Collies were used to determine the impact of ABCB1 genotype and phenotype on the plasma pharmacokinetics of fexofenadine"s (Fex) R- and S-enantiomers after bolus Fex administration, as human P-gp exhibits stereoselectivity.	fexofenadine	119-131	ATP binding cassette subfamily B member 1	Homo sapiens	56-61
30009812-11	2018	These results indicate that both blood brain barrier penetrating (chlorpheniramine) and poorly penetrating (fexofenadine) histamine H1 receptor antagonists could improve the neuropathic pain sign, but only the blood brain barrier penetrating histamine H2 receptor antagonist (ranitidine) could produce anti-allodynic effects in the TNT model of neuropathic pain in rats.	fexofenadine	108-120	histamine receptor H 1	Rattus norvegicus	122-143
29635947-5	2018	Expert opinion: Differences in pharmacokinetics between fexofenadine enantiomers were caused by organic anion transporting polypeptide (OATP) 2B1, with a minor contribution from P-glycoprotein (P-gp).	fexofenadine	56-68	solute carrier organic anion transporter family member 2B1	Homo sapiens	96-145
29635947-7	2018	P-gp inducers, carbamazepine, and inhibitors such as itraconazole and verapamil show greater effects on the pharmacokinetics of (S)-fexofenadine.	fexofenadine	128-144	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
29635947-8	2018	Apple juice and grape fruit juice, OATP2B1 inhibitors, significantly decrease the exposure of both fexofenadine enantiomers, particularly the (S)-enantiomer, but do not change the t1/2.	fexofenadine	99-111	solute carrier organic anion transporter family member 2B1	Homo sapiens	35-42
29635947-9	2018	Rifampicin significantly increases plasma concentrations of both enantiomers through inhibition of OATP1B3, whereas enantioselectivity of fexofenadine uptake by OATP1B3-expressing cells has not been observed.	fexofenadine	138-150	solute carrier organic anion transporter family member 1B3	Homo sapiens	161-168
29635947-10	2018	Combinations of multiple transporters such as OATP2B1 and P-gp facilitate enantioselective disposition of fexofenadine.	fexofenadine	106-118	solute carrier organic anion transporter family member 2B1	Homo sapiens	46-53
29635947-10	2018	Combinations of multiple transporters such as OATP2B1 and P-gp facilitate enantioselective disposition of fexofenadine.	fexofenadine	106-118	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
29378195-8	2018	Treatment of HepG2 cells with other H1 receptor antagonists including fexofenadine, cetirizine, and diphenhydramine increased apo A-I levels in a dose-dependent manner while treatment with H2 receptor antagonists including cimetidine, famotidine, and ranitidine had no effect.	fexofenadine	70-82	apolipoprotein A1	Homo sapiens	126-133
27109454-0	2017	Binding of fexofenadine hydrochloride to bovine serum albumin: structural considerations by spectroscopic techniques and molecular docking.	fexofenadine	11-37	albumin	Homo sapiens	48-61
28544909-0	2017	Can human allergy drug fexofenadine, an antagonist of histamine (H1) receptor, be used to treat dog and cat?	fexofenadine	23-35	histamine receptor H1	Homo sapiens	54-77
28521025-5	2017	Then we explored pharmacological rescue strategies on As2O3-induced LQTS, and found that 4 therapeutic agents exert rescue efficacy via 3 different pathways: fexofenadine and astemizole facilitate hERG trafficking via promotion of channel-chaperone formation after As2O3 incubation; ranolazine slows hERG degradation in the presence of As2O3; and resveratrol shows significant attenuation on calcium current increase triggered by As2O3.	fexofenadine	158-170	ETS transcription factor ERG	Homo sapiens	197-201
28521025-5	2017	Then we explored pharmacological rescue strategies on As2O3-induced LQTS, and found that 4 therapeutic agents exert rescue efficacy via 3 different pathways: fexofenadine and astemizole facilitate hERG trafficking via promotion of channel-chaperone formation after As2O3 incubation; ranolazine slows hERG degradation in the presence of As2O3; and resveratrol shows significant attenuation on calcium current increase triggered by As2O3.	fexofenadine	158-170	ETS transcription factor ERG	Homo sapiens	300-304
28102715-0	2017	Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.	fexofenadine	55-67	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	79-93
28102715-2	2017	Therefore, purpose of this study was to evaluate the effect of capsaicin on intestinal absorption and bioavailability of fexofenadine, a P-gp substrate in rats.	fexofenadine	121-133	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	137-141
28102715-9	2017	CONCLUSIONS: Capsaicin pretreatment significantly enhanced the intestinal absorption and bioavailability of fexofenadine in rats likely by inhibition of P-gp mediated cellular efflux, suggesting that the combined use of capsaicin with P-gp substrates may require close monitoring for potential drug interactions.	fexofenadine	108-120	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	153-157
28102715-9	2017	CONCLUSIONS: Capsaicin pretreatment significantly enhanced the intestinal absorption and bioavailability of fexofenadine in rats likely by inhibition of P-gp mediated cellular efflux, suggesting that the combined use of capsaicin with P-gp substrates may require close monitoring for potential drug interactions.	fexofenadine	108-120	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	235-239
28188296-1	2017	The aim of this study was to determine the effects of garlic and ginkgo herbal extracts on the pharmacokinetics of the P-glycoprotein (P-gp)/organic anion-transporting polypeptides (Oatps) substrate fexofenadine.	fexofenadine	199-211	phosphoglycolate phosphatase	Rattus norvegicus	135-139
28301431-5	2017	In addition, oral fexofenadine was used as an in vivo probe for P-gp activity.	fexofenadine	18-30	ATP binding cassette subfamily B member 1	Homo sapiens	64-68
27109454-1	2017	The binding interaction of peripheral H1 receptor antagonist drug, fexofenadine hydrochloride to bovine serum albumin (BSA) is investigated by fluorescence spectroscopy in combination with UV-absorption spectroscopy under physiological conditions.	fexofenadine	67-93	albumin	Homo sapiens	104-117
28040476-7	2017	The mutation of Asp2.50 (Asp73) to asparagine abrogated NaCl-induced reductions in affinities for histamine and d-chlorpheniramine, but not NaCl-induced increases in the affinity for fexofenadine.	fexofenadine	183-195	beta-secretase 1	Homo sapiens	16-20
27981349-0	2017	The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.	fexofenadine	53-65	ATP binding cassette subfamily B member 1	Homo sapiens	69-83
27981349-2	2017	The aim of this study was to evaluate the effect of PIP on the pharmacokinetics of fexofenadine (FEX), a P-gp substrate, in healthy volunteers.	fexofenadine	83-95	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
27981349-2	2017	The aim of this study was to evaluate the effect of PIP on the pharmacokinetics of fexofenadine (FEX), a P-gp substrate, in healthy volunteers.	fexofenadine	97-100	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
27843000-0	2017	Changes in gene expression induced by histamine, fexofenadine and osthole: Expression of histamine H1 receptor, COX-2, NF-kappaB, CCR1, chemokine CCL5/RANTES and interleukin-1beta in PBMC allergic and non-allergic patients.	fexofenadine	49-61	histamine receptor H1	Homo sapiens	89-110
27074034-5	2016	Subjects were randomly assigned to take either a combined H1R and H2R antagonist (fexofenadine and ranitidine) or a control placebo.	fexofenadine	82-94	histamine receptor H2	Homo sapiens	66-69
28090646-0	2017	Influence of P-glycoprotein on the disposition of fexofenadine and its enantiomers.	fexofenadine	50-62	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
28090646-3	2017	Using fexofenadine as a model compound, we developed and validated HPLC-fluorescence methods to determine the effect of P-gp on the disposition of fexofenadine and its enantiomers.	fexofenadine	6-18	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
28090646-3	2017	Using fexofenadine as a model compound, we developed and validated HPLC-fluorescence methods to determine the effect of P-gp on the disposition of fexofenadine and its enantiomers.	fexofenadine	147-159	ATP binding cassette subfamily B member 1	Homo sapiens	120-124
28090646-8	2017	KEY FINDINGS: This study demonstrates that P-gp prefers to transport (S)-fexofenadine, and P-gp deficiency causes the increase in both (R)-fexofenadine and (S)-fexofenadine in plasma.	fexofenadine	69-85	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
28090646-8	2017	KEY FINDINGS: This study demonstrates that P-gp prefers to transport (S)-fexofenadine, and P-gp deficiency causes the increase in both (R)-fexofenadine and (S)-fexofenadine in plasma.	fexofenadine	156-172	ATP binding cassette subfamily B member 1	Homo sapiens	43-47
28090646-9	2017	Racemic fexofenadine, (R)-fexofenadine and (S)-fexofenadine were increased in ABCB1-1Delta Collies (118.7, 72.0 and 48.3 ng/ml) compared to wild-type Collies (25.0, 16.5 and 7.7 ng/ml) at 1 h postadministration.	fexofenadine	8-20	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
28090646-9	2017	Racemic fexofenadine, (R)-fexofenadine and (S)-fexofenadine were increased in ABCB1-1Delta Collies (118.7, 72.0 and 48.3 ng/ml) compared to wild-type Collies (25.0, 16.5 and 7.7 ng/ml) at 1 h postadministration.	fexofenadine	43-59	ATP binding cassette subfamily B member 1	Homo sapiens	78-83
28090646-10	2017	The results demonstrate that the stereoselectivity of P-gp plays a key role in the disposition of fexofenadine enantiomers.	fexofenadine	98-110	ATP binding cassette subfamily B member 1	Homo sapiens	54-58
27023466-5	2016	One hundred twenty milligrams fexofenadine, an OATP1A2 substrate, was taken in 1 day before the first folic acid intake, and again on the ninth day of 1,25(OH)2D3 intake.	fexofenadine	30-42	solute carrier organic anion transporter family member 1A2	Homo sapiens	47-54
26798172-0	2015	Does Ethnic Variability Exist in the Systemic Exposures of OATP1A2 Substrates-Fexofenadine in Taiwanese?	fexofenadine	78-90	solute carrier organic anion transporter family member 1A2	Homo sapiens	59-66
26922536-8	2016	CONCLUSIONS: RSV significantly enhanced the exposure of FEX in rats likely by the inhibition of P-glycoprotein (P-gp) mediated efflux during the intestinal absorption, suggesting that there is a potential pharmacokinetic interaction between RSV and FEX.	fexofenadine	56-59	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	96-110
26922536-8	2016	CONCLUSIONS: RSV significantly enhanced the exposure of FEX in rats likely by the inhibition of P-glycoprotein (P-gp) mediated efflux during the intestinal absorption, suggesting that there is a potential pharmacokinetic interaction between RSV and FEX.	fexofenadine	56-59	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	112-116
26922536-8	2016	CONCLUSIONS: RSV significantly enhanced the exposure of FEX in rats likely by the inhibition of P-glycoprotein (P-gp) mediated efflux during the intestinal absorption, suggesting that there is a potential pharmacokinetic interaction between RSV and FEX.	fexofenadine	249-252	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	112-116
26474764-4	2016	However, the above hypothesis was refuted by another published human pharmacokinetic study of fexofenadine formulated with chitosan formulation - in this work it was unambiguously shown that chitosan helped in enhanced absorption of fexofenadine which is a well-known Pgp substrate.	fexofenadine	94-106	phosphoglycolate phosphatase	Homo sapiens	268-271
26474764-4	2016	However, the above hypothesis was refuted by another published human pharmacokinetic study of fexofenadine formulated with chitosan formulation - in this work it was unambiguously shown that chitosan helped in enhanced absorption of fexofenadine which is a well-known Pgp substrate.	fexofenadine	233-245	phosphoglycolate phosphatase	Homo sapiens	268-271
26467209-0	2016	Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.	fexofenadine	142-154	ATP binding cassette subfamily B member 1	Homo sapiens	41-55
25953731-0	2015	Design of Fexofenadine Prodrugs Based on Tissue-Specific Esterase Activity and Their Dissimilar Recognition by P-Glycoprotein.	fexofenadine	10-22	ATP binding cassette subfamily B member 1	Homo sapiens	111-125
25908246-8	2015	OATP1A2-mediated uptake of zolmitriptan, rosuvastatin, and fexofenadine across monolayers increased with increasing OATP1A2 protein expression.	fexofenadine	59-71	solute carrier organic anion transporter family member 1A2	Homo sapiens	0-7
26204515-5	2015	Although fexofenadine-treated mice had decreased antigen-specific IgE levels as well as lower splenocyte IL-5 and IFNgamma production, they exhibited a greater than fourfold rise in eosinophil numbers at the tissue site where adult L. sigmodontis worms reside.	fexofenadine	9-21	interleukin 5	Mus musculus	105-109
25908246-8	2015	OATP1A2-mediated uptake of zolmitriptan, rosuvastatin, and fexofenadine across monolayers increased with increasing OATP1A2 protein expression.	fexofenadine	59-71	solute carrier organic anion transporter family member 1A2	Homo sapiens	116-123
25908246-9	2015	OATP1A2 counteracted P-gp efflux for cosubstrates zolmitriptan and fexofenadine.	fexofenadine	67-79	solute carrier organic anion transporter family member 1A2	Homo sapiens	0-7
25908246-9	2015	OATP1A2 counteracted P-gp efflux for cosubstrates zolmitriptan and fexofenadine.	fexofenadine	67-79	ATP binding cassette subfamily B member 1	Homo sapiens	21-25
25263393-2	2015	Simultaneous administration of single- or multiple-dose rifampicin 600 mg significantly increases the concentrations of fexofenadine enantiomers by inhibiting OATP transporters.	fexofenadine	120-132	solute carrier organic anion transporter family member 1A2	Homo sapiens	159-163
25159828-4	2015	Fexofenadine (FEX), a P-gp/OATP substrate, can be considered a suitable probe.	fexofenadine	0-12	phosphoglycolate phosphatase	Homo sapiens	22-26
25159828-4	2015	Fexofenadine (FEX), a P-gp/OATP substrate, can be considered a suitable probe.	fexofenadine	0-12	solute carrier organic anion transporter family member 1A2	Homo sapiens	27-31
25159828-4	2015	Fexofenadine (FEX), a P-gp/OATP substrate, can be considered a suitable probe.	fexofenadine	14-17	phosphoglycolate phosphatase	Homo sapiens	22-26
25159828-4	2015	Fexofenadine (FEX), a P-gp/OATP substrate, can be considered a suitable probe.	fexofenadine	14-17	solute carrier organic anion transporter family member 1A2	Homo sapiens	27-31
25538104-8	2015	Fexofenadine significantly inhibited the upregulated expression of IL-8 in HCT116 and COLO205 cells stimulated with TNF-alpha.	fexofenadine	0-12	C-X-C motif chemokine ligand 8	Homo sapiens	67-71
25538104-8	2015	Fexofenadine significantly inhibited the upregulated expression of IL-8 in HCT116 and COLO205 cells stimulated with TNF-alpha.	fexofenadine	0-12	tumor necrosis factor	Homo sapiens	116-125
25538104-11	2015	In addition, the induction of ER stress markers caspase-12 and p-eukaryotic initiation factor 2 (eIF2)-alpha was significantly suppressed by the pretreatment of fexofenadine.	fexofenadine	161-173	caspase 12	Mus musculus	48-58
25538104-11	2015	In addition, the induction of ER stress markers caspase-12 and p-eukaryotic initiation factor 2 (eIF2)-alpha was significantly suppressed by the pretreatment of fexofenadine.	fexofenadine	161-173	eukaryotic translation initiation factor 2A	Mus musculus	97-108
25538104-14	2015	Finally, fexofenadine significantly reduced the severity of colitis and the immunoreactivity of caspase-12 and p-eIF2-alpha in IL-10(-/-) mice as compared with controls.	fexofenadine	9-21	caspase 12	Mus musculus	96-106
25538104-14	2015	Finally, fexofenadine significantly reduced the severity of colitis and the immunoreactivity of caspase-12 and p-eIF2-alpha in IL-10(-/-) mice as compared with controls.	fexofenadine	9-21	interleukin 10	Mus musculus	127-132
25712660-3	2015	Hence, the present study was performed to investigate the effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine, a P-gp substrate in rats.	fexofenadine	129-141	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	145-149
25712660-9	2015	CONCLUSIONS: Diosmin significantly enhanced the oral bioavailability of fexofenadine by the inhibition of P-gp mediated drug efflux during the intestinal absorption.	fexofenadine	72-84	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	106-110
25263393-10	2015	Therefore, the interactive mechanism of multidose rifampicin may occur through a combination of OATP and P-gp transporters, thereby altering the pharmacokinetics of fexofenadine enantiomers.	fexofenadine	165-177	solute carrier organic anion transporter family member 1A2	Homo sapiens	96-100
25263393-10	2015	Therefore, the interactive mechanism of multidose rifampicin may occur through a combination of OATP and P-gp transporters, thereby altering the pharmacokinetics of fexofenadine enantiomers.	fexofenadine	165-177	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
25501360-13	2014	Fexofenadine, levocetirizine, desloratadine, olopatadine, loratadine, and mequitazine all had a PIR for subjective ratings of 0, but the upper limits of the 95% CIs were all in excess of 1, although fexofenadine (PIR = 2.57) was the lowest.	fexofenadine	0-12	ring finger protein 144B	Homo sapiens	213-220
25759055-7	2015	The findings suggested that a combination of multiple transporters involving organic anion transporting polypeptide (OATP) 2B1, P-glycoprotein (P-gp), and multidrug resistance-associated protein 2 (MRP2) react to stereoselective fexofenadine exposure.	fexofenadine	229-241	solute carrier organic anion transporter family member 2B1	Homo sapiens	77-126
25759055-7	2015	The findings suggested that a combination of multiple transporters involving organic anion transporting polypeptide (OATP) 2B1, P-glycoprotein (P-gp), and multidrug resistance-associated protein 2 (MRP2) react to stereoselective fexofenadine exposure.	fexofenadine	229-241	ATP binding cassette subfamily B member 1	Homo sapiens	128-142
25759055-7	2015	The findings suggested that a combination of multiple transporters involving organic anion transporting polypeptide (OATP) 2B1, P-glycoprotein (P-gp), and multidrug resistance-associated protein 2 (MRP2) react to stereoselective fexofenadine exposure.	fexofenadine	229-241	ATP binding cassette subfamily B member 1	Homo sapiens	144-148
25759055-7	2015	The findings suggested that a combination of multiple transporters involving organic anion transporting polypeptide (OATP) 2B1, P-glycoprotein (P-gp), and multidrug resistance-associated protein 2 (MRP2) react to stereoselective fexofenadine exposure.	fexofenadine	229-241	ATP binding cassette subfamily C member 2	Homo sapiens	155-196
25759055-7	2015	The findings suggested that a combination of multiple transporters involving organic anion transporting polypeptide (OATP) 2B1, P-glycoprotein (P-gp), and multidrug resistance-associated protein 2 (MRP2) react to stereoselective fexofenadine exposure.	fexofenadine	229-241	ATP binding cassette subfamily C member 2	Homo sapiens	198-202
25759055-9	2015	Coadministration of P-gp inducer/inhibitors significantly altered the pharmacokinetics of fexofenadine enantiomers.	fexofenadine	90-102	ATP binding cassette subfamily B member 1	Homo sapiens	20-24
25759055-11	2015	Moreover, in in vitro studies, the uptake of both fexofenadine enantiomers into OATP2B1 cRNA-injected oocytes was significantly higher than that into water-injected oocytes, and this effect was greater for (R)-fexofenadine.	fexofenadine	50-62	solute carrier organic anion transporter family member 2B1	Homo sapiens	80-87
25759055-12	2015	Taken together, these studies indicated that multiple transporters including P-gp, OATPs, and MRP2 play important roles in fexofenadine enantiomer pharmacokinetics.	fexofenadine	123-135	ATP binding cassette subfamily B member 1	Homo sapiens	77-81
25759055-12	2015	Taken together, these studies indicated that multiple transporters including P-gp, OATPs, and MRP2 play important roles in fexofenadine enantiomer pharmacokinetics.	fexofenadine	123-135	ATP binding cassette subfamily C member 2	Homo sapiens	94-98
25759055-13	2015	Furthermore, OATP2B1 is a key determinant of the stereoselective pharmacokinetics of fexofenadine, and drug transporters may have chiral discrimination ability.	fexofenadine	85-97	solute carrier organic anion transporter family member 2B1	Homo sapiens	13-20